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Abstract
The work described in this thesis deals with two pore forming toxins, namely Arcanobac-
terium pyogenes pyolysin and Streptococcus agalactiae CAMP factor.
Pyolysin (PLO) belongs to the homologous group of cholesterol-dependent cytolysins.
In chapter 2, it is shown that PLO can form small oligomers in solution, without the re-
quirement for any membranes or membrane lipids. These small oligomers may aggregate
into larger ones on membranes; however, in solution, they apparently do not grow by ad-
dition of further monomers, as their size is virtually unaffected by variations of incuba-
tion time or toxin concentration. The small, solution-derived oligomers retain hemolytic
activity. The membrane lesions observed by electron microscopy are similar to those that
are formed by monomeric PLO, except that they are mostly incomplete and arc-shaped,
as opposed to the predominantly ring-shaped ones formed by monomeric PLO when di-
rectly incubated with membranes. This structural difference corresponds to a detectable
difference in functional pore size, as determined by marker release experiments. Thus,
arc-shaped PLO oligomers may form functional pores of reduced size.
In chapter 3, we show that liposomes that contain phosphatidylcholine and ceramide
but no cholesterol or other sterol are susceptible to the cholesterol-dependent cytolysin
pyolysin. Pyolysin, at a low rate, forms small oligomers in solution. The solution-derived
oligomers are more effective on ceramide-containing liposomes than the monomeric
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toxin. In contrast, they have much lower activity on liposome membranes that contain
cholesterol but no ceramide. Our findings therefore show that at least one member of the
‘cholesterol-dependent cytolysins’ is in fact not strictly dependent on the sterol. In addi-
tion, in conjunction with previous data, they suggest that the requirement for cholesterol
involves early or intermediate stages of oligomer formation, rather than the final event of
membrane insertion.
Chapter 4 of this thesis concerns Streptococcus agalactiae CAMP factor. CAMP
factor has previously been reported to bind the Fc fragments of immunoglobulin G (IgG)
and has therefore also been called ‘protein B’, in analogy to protein A of Staphylococcus
aureus. We attempted to characterize the interaction of protein B with IgG in more detail.
In contrast to protein A, CAMP factor does not inhibit the activation of complement by
hemolysin antibodies bound to sheep red cell surfaces. IgG also failed to inhibit the co-
hemolytic activity of CAMP factor, which it displays on sphingomyelinase-treated sheep
red cells; this is in disagreement with previous findings. After co-incubation, CAMP
factor and IgG were cleanly separated by gel filtration. Therefore, CAMP factor does
not detectably bind to IgG.
iv
Acknowledgements
First of all, I would like to express my special thanks to Dr. Michael Palmer for his
supervision, advice, and guidance from the very early stage of this research. Above all
and the most needed, he provided me unflinching encouragement and support in various
ways. His truly scientist intuition has made him a constant oasis of ideas and passions in
science, which exceptionally inspired and enriched my growth as a student, a researcher
and aspiring scientist. I am indebted to him more than he knows.
I would like to extend my thanks to my advisory committee members, Dr. John
Honek, Dr. Janet Wood and Dr. Guy Guillemette for their useful suggestions and com-
ments.
I would like to thank my lab members Lisa Pokrajac, David Donkor, Ryan Mui, Oscar
Zhang, Dr. Naghmeh Sarri-Sarraf, Dr. Dinath Ratnayake and Dr. Shenhui Lang for their
support. In addition i would like to thank Dr. Stephen Billington and Dr. Guenter Scholz
for their help. Special thanks are extended to my friends Kamal, Rand and Ahmad for
the wonderful moments we had together.
Finally, I would like to express my gratitude to my wonderful wife Reham, for her




To my beloved wife and my little two angels
To my mother and brothers
To the soul of my father
To everyone supported me
vi
Contents
1 Introduction and Literature Review 1
1.1 Introduction to Pore-forming Toxins . . . . . . . . . . . . . . . . . . . 2
1.2 Classification of Pore Forming Toxins . . . . . . . . . . . . . . . . . . 4
1.3 β-Pore Forming Toxins . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.3.1 Staphylococcus aureus α-Hemolysin . . . . . . . . . . . . . . 9
1.3.2 Anthrax Toxin Protective Antigen (PA) . . . . . . . . . . . . . 12
1.3.3 Vibrio cholerae Cytolysin . . . . . . . . . . . . . . . . . . . . 14
1.4 Cholesterol-Dependent Cytolysins . . . . . . . . . . . . . . . . . . . . 18
1.4.1 CDC Monomer Structure . . . . . . . . . . . . . . . . . . . . . 18
1.4.2 The Role of Cholesterol in the Activity of CDCs . . . . . . . . 21
1.4.3 The Pore Forming Mechanism of CDCs . . . . . . . . . . . . . 22
vii
1.4.4 Role of CDCs in Pathogenesis . . . . . . . . . . . . . . . . . . 25
1.5 Pyolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.6 Streptococcus agalactiae CAMP Factor . . . . . . . . . . . . . . . . . 34
1.6.1 Streptococcus agalactiae . . . . . . . . . . . . . . . . . . . . . 34
1.7 Research Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2 The Cholesterol-Dependent Cytolysin Pyolysin forms small,
hemolytically active oligomers in solution 40
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.2.1 Production and Purification of Histidine-tagged PLO (His-PLO) 43
2.2.2 Cysteine-specific Labeling of Mutant N90C . . . . . . . . . . . 43
2.2.3 Size Exclusion Chromatography . . . . . . . . . . . . . . . . . 44
2.2.4 Lysis of Red Blood Cells . . . . . . . . . . . . . . . . . . . . . 44
2.2.5 Marker Release Experiments . . . . . . . . . . . . . . . . . . . 45
2.2.6 Electron Microscopy . . . . . . . . . . . . . . . . . . . . . . . 46
2.2.7 Preparation of Liposomes . . . . . . . . . . . . . . . . . . . . 47
2.2.8 Preparation of Erythrocyte Membranes . . . . . . . . . . . . . 47
viii
2.2.9 Circular Dichroism Spectroscopy . . . . . . . . . . . . . . . . 47
2.2.10 Electrophoresis . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.2.11 Protein Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.2.12 Spectrofluorimetry . . . . . . . . . . . . . . . . . . . . . . . . 49
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.3.1 Spontaneous Oligomerization of PLO in Solution . . . . . . . . 50
2.3.2 Conformation of the Subunits in Solution-Derived
Oligomers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
2.3.3 Hemolytic Activity of Solution-Derived PLO Oligomers . . . . 57
2.3.4 Electron Microscopy of Pores Formed by Solution-Derived Oli-
gomers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.3.5 Mechanism of Pore-Formation by Solution-Derived Oligomers . 61
2.3.6 Functional Size of Pores Formed by Solution-Derived Oligomers 65
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3 A Cholesterol-Dependent Cytolysin (Pyolysin) Permeabilizes
Cholesterol-Free Liposomes 75
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
ix
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.2.1 Production and Purification of Histidine-tagged PLO . . . . . . 78
3.2.2 Lysis of Red Blood Cells . . . . . . . . . . . . . . . . . . . . . 78
3.2.3 Preparation of Liposomes . . . . . . . . . . . . . . . . . . . . 78
3.2.4 Calcein Release Assay . . . . . . . . . . . . . . . . . . . . . . 79
3.2.5 Electron Microscopy . . . . . . . . . . . . . . . . . . . . . . . 80
3.2.6 Protein Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
3.2.7 Spectrofluorimetry . . . . . . . . . . . . . . . . . . . . . . . . 80
3.2.8 Binding of PLO to Liposomes . . . . . . . . . . . . . . . . . . 81
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.3.1 Activity of PLO on Sphingomyelinase-Pretreated Erythrocytes
and Ceramide-Containing Liposomes . . . . . . . . . . . . . . 82
3.3.2 PLO Permeabilizes Liposomes Containing Ceramide but no Chole-
sterol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
3.3.3 The Effect of Ceramide and of Cholesterol Concentrations on
Membrane Susceptibility to PLO . . . . . . . . . . . . . . . . 86
3.3.4 Oligomerization of PLO on Liposome Membranes . . . . . . . 88
x
3.3.5 The Role of Solution-Derived Oligomers in the Permeabilization
of Ceramide-Containing Liposomes . . . . . . . . . . . . . . . 91
3.3.6 Binding of Solution-Derived Oligomers to Liposomes
Containing Cholesterol . . . . . . . . . . . . . . . . . . . . . . 94
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4 Streptococcus agalactiae CAMP Factor / Protein B Does Not Bind to Human
IgG 98
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.2.1 Expression and Purification of Wild Type and Recombinant CAMP
Factor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.2.2 Fluorescein Labeling of Mutant Recombinant CAMP Factor . . 101
4.2.3 Hemolysis Assay of Inhibition of Complement Activation . . . 101
4.2.4 Co-hemolytic Activity Assay . . . . . . . . . . . . . . . . . . . 102
4.2.5 Size Exclusion Chromatography . . . . . . . . . . . . . . . . . 102
4.2.6 Electrophoresis . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.2.7 Spectrofluorimetry . . . . . . . . . . . . . . . . . . . . . . . . 103
xi
4.2.8 Protein Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.2.9 Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . . 104
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.3.1 CAMP Factor Does Not Inhibit Antibody/Complement-Mediated
Hemolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.3.2 Immunoglobulin G Does Not Inhibit the Co-Hemolytic Activity
of CAMP Factor . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.3.3 CAMP Factor Does Not Bind Human Immunoglobulin G . . . . 108
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5 Summary and Future Considerations 115
xii
List of Tables
1.1 List of known members of the cholesterol-dependent cytolysins. . . . . 19
1.2 The conserved undecapeptide sequence of CDCs. . . . . . . . . . . . . 32
2.1 Fluorescence lifetimes of pyolysin mutant T90C, labeled with fluorescein
and rhodamine, under various experimental conditions. . . . . . . . . . 64
xiii
List of Figures
1.1 The general steps involved in membrane pore formation by PFTs. . . . 3
1.2 Ribbon representations of α-PFT structures. . . . . . . . . . . . . . . . 6
1.3 Ribbon representations of β-PFT structures. . . . . . . . . . . . . . . . 8
1.4 Staphylococcus aureus α-hemolysin heptameric pore. . . . . . . . . . . 10
1.5 Protective antigen heptamer. . . . . . . . . . . . . . . . . . . . . . . . 13
1.6 Ribbon representative of monomeric PA . . . . . . . . . . . . . . . . . 15
1.7 Ribbon representation of VCC pro-toxin. . . . . . . . . . . . . . . . . 17
1.8 Crystal structure of PFO. . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.9 The mechanism of pore-formation by CDCs . . . . . . . . . . . . . . . 24
1.10 Phylogenetic tree of protein sequences of the cholesterol-dependent cy-
tolysins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
xiv
1.11 Electron microscopy of the pores formed by CAMP factor on sheep red
cell membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.1 Size exclusion chromatography elution profiles of 2 mg/ml PLO . . . . 51
2.2 Rechromatographed monomers and oligomers immediately after isolation. 52
2.3 Size exclusion chromatography elution profiles of 2 mg/ml monomeric
PLO (isolated by gel filtration) after incubation at 20◦C for 12 hours. . . 53
2.4 Size exclusion chromatography elution profiles of unfractionated PLO
was concentrated to 10 mg/ml PLO and incubated for 4 hours at 37◦C
before gel filtration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.5 Far-UV CD spectra of PLO . . . . . . . . . . . . . . . . . . . . . . . . 56
2.6 Hemolysis of human erythrocytes by monomeric and oligomeric PLO. 57
2.7 Hemolysis kinetics of monomeric and oligomeric PLO. . . . . . . . . . 58
2.8 Electron microscopy of pores formed by oligomeric and monomeric forms
of PLO on red blood cells. . . . . . . . . . . . . . . . . . . . . . . . . 60
2.9 Electron microscopy of solution-derived oligomers in the absence of red
blood cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.10 Release of FITC-dextran 250 and 2000 from human erythrocyte ghosts
by monomeric PLO and by solution-derived oligomers. . . . . . . . . . 67
xv
2.11 Hypothetical explanations for the limited size of oligomers forming in
solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2.12 Hypothetical oligomer size distributions for the cases of a size-independent
and a size-proportional rate constant. . . . . . . . . . . . . . . . . . . . 73
3.1 Hemolysis of human erythrocytes by PLO with and without pre-treatment
with sphingomyelinase . . . . . . . . . . . . . . . . . . . . . . . . . . 83
3.2 Electron microscopy of pores formed by PLO on red blood cells with or
without pre-treatment with sphingomyelinase . . . . . . . . . . . . . . . 84
3.3 Calcein release assay for liposomes composed of 35:65 cholesterol:DMPC
and 35:20:45 cholesterol:ceramide:DMPC by mole with PLO. . . . . . 85
3.4 Calcein release assay for liposomes composed of 35% cholesterol and
35% ceramide by mole with PLO. . . . . . . . . . . . . . . . . . . . . 87
3.5 Calcein release assay for liposomes composed of 35% Ceramide and
50% ceramide by mole with PLO. . . . . . . . . . . . . . . . . . . . . 89
3.6 Quenching of Rhodamine-labeled N90C PLO on liposomes of different
composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.7 Calcein release assay for liposomes composed of 50% Cholesterol by
mole with monomeric and oligomeric PLO. . . . . . . . . . . . . . . . 92
xvi
3.8 Calcein release assay for liposomes composed of 50% Ceramide by mole
with monomeric and oligomeric PLO. . . . . . . . . . . . . . . . . . . 93
4.1 Mass spectrometry of wild type CAMP factor purified from S. agalactiae 106
4.2 Co-hemolytic activity of wild type and recombinant CAMP factor. . . . 107
4.3 Hemolysis assay for inhibition of complement activation. . . . . . . . . 109
4.4 Co-hemolytic activities of wild type and recombinant CAMP factor in
the presence of human IgG. . . . . . . . . . . . . . . . . . . . . . . . . 111
4.5 Analysis of CAMP factor binding to IgG by size exclusion chromatog-






C-12 Ceramide : N-lauroyl-D-erythro-shingosine; 
CD : Circular Dichroism; 
CDC : Cholesterol Dependent Cytolysin; 
CYT : Cytotoxin; 
DMPC : 1,2-dimyristoyl-sn-glycerol-3-phosphocholine; 
EM : Electron microscopy; 
EF : Edema Factor; 
FRET : Fluorescence Resonance Energy Transfer; 
GBS : Group B Streptococcus; 
GPI : Glycosylphosphatidylinositol; 
HBS : HEPES Buffer Saline; 
IgG : Immunoglobulin G; 
IgM : Immunoglobulin M; 
ILY : intermedilysin; 
IPTG : Isopropyl-β-D-thiogalactopyranoside; 
LB : Luria bertani broth; 
LF : Lethal Factor; 
LLO : Listeriolysin; 
 xix
MDT :  Membrane Damaging Toxins; 
OD : Optical density; 
PA : Protective Antigen; 
PBS : Phosphate Buffered Saline; 
PC : Phosphatidylcholine; 
PDB : Protein Data Bank; 
PFO :  Perfringolysin; 
PFT :  Pore Forming Toxins; 
PLO : Pyolysin; 
PMN : Polymorphonuclear cell; 
RPM : Revolution Per Minute; 
SDO : Solution Derived Oligomers; 
SDS : Sodium Dodecyl Sulfate; 
SDS-PAGE : Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis; 
SLO : Streptolysin O; 
TBS : Tris Buffer Saline; 
UV : Ultra Violet; 
VCC : Vibrio cholera Cytolysin; 
 
Chapter 1
Introduction and Literature Review
1
1.1 Introduction to Pore-forming Toxins
An evolutionary outcome of the host-pathogen relationship between higher eukaryotes
and bacteria is the development and production of virulence factors that enable the
pathogen to invade the host. These bacterial virulence factors are most often protein
molecules (or toxins).
Of the more than 300 protein toxins characterized to date, at least one third act by dis-
rupting membranes (and are therefore known as membrane-damaging toxins (MDT))[3].
MDT can be classified into three types, based on their mechanisms of action against
target cell membranes:
1. Enzymatically active cytolysins, which act on lipids in the cell membrane, leading
to its degradation.
2. Tensio-active cytolysins, which solubilize cell membranes by a detergent-like ac-
tion.
3. Pore-forming toxins [13, 4].
In contrast to tensio-active cytolysins, pore-forming toxins form discrete pores or chan-
nels in cell membranes, disrupting the permeability barrier and leading eventually to cell
death (Fig. 1.1). Pore-forming toxins typically behave as hydrophilic proteins prior to





Toxin is secreted and binds to 
receptors on the cell surface
Oligomerization of molecules
Insertion into the cell membrane
Figure 1.1: The general steps involved in membrane pore formation by PFTs.
membranes, they must undergo a series of conformational changes that will expose or
generate new hydrophobic surfaces which can penetrate the apolar core of the lipid bi-
layer.
Organisms other than bacteria can also produce cytolytic toxins. These organisms
include certain insects, poisonous reptiles and stinging marine invertebrates.
In addition to ‘pure’ pore-forming toxins, there also are bacterial toxins that contain
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pore-forming subunits or domains in addition to enzymatic ones; well-known examples
are cholera toxin, anthrax toxin, and diphtheria toxin. The toxic enzyme components
of these toxins act intracellularly, and the pore-forming components enable the enzymes
to cross the membrane barrier and reach the cytosol. Toxins that follow this functional
paradigm are often referred to as ‘A-B toxins’; the ‘A’ refers to the enzymatically active
component, whereas the B represents the membrane-binding and pore-forming compo-
nent.
1.2 Classification of Pore Forming Toxins
Pore-forming toxins (PFTs) can be classified in several ways. For instance, they may be
classified according to the organism that produces them, or to some specific characteristic
that is required for activity. However, the most useful classification is based on structural
features as described by Gouaux in 1997 [55]. At the most general level of this scheme,
pore-forming toxins are considered as either α- or β-PFTs.
α-PFTs are predicted to form pores using α-helices. These toxin molecules tend to be
highly α-helical, with the larger ones having pore-forming domains consisting of a three-
layer structure of up to ten α-helices sandwiching a centrally positioned hydrophobic
helical hairpin (Fig. 1.2). This hairpin is thought to drive the initial steps of the insertion
process.
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Some examples of members in this class are the pore-forming colicins [124], Pseu-
domonas aeruginosa exotoxin A [1], the insecticidal Bacillus thuringiensis δ-endotoxins
(Cry)[86] and diphtheria toxin [27].
Proteins related to bacterial pore forming toxins also occur in eukaryotic organisms.
An example are the members of the Bcl-2 and Bcl-x family of apoptotic proteins, among
which Bcl-2 was the first one to be identified in B-cell leukemic cells. These proteins
have been shown to be structurally similar to α-PFTs and also form ion channels in a
fashion similar to the toxins, although there is no homology at primary and structure
level [95, 105].
The other major class of pore-forming toxins, the β-PFTs, have been shown or are
predicted to insert into membranes to form β-barrels. β-PFTs have quite different ter-
tiary and quaternary structures from α-PFTs. The monomeric structures are more com-
pact than those of α-PFTs. As indicated by their name, all β-PFTs consist mainly of
β-structures, (Fig. 1.3). The class includes Aeromonas hydrophila aerolysin, Clostrid-
ium septicum α-toxin, Staphylococcus aureus α-hemolysin, Pseudomonas aeruginosa
cytotoxin, the protective antigen component of anthrax toxin, the insecticidal Bacillus
thuringiensis Cyt δ-endotoxins, and the family of cholesterol-dependent cytolysins.
The oligomers of β-PFTs are usually fairly stable and remain intact even after solubi-




Figure 1.2: Ribbon representations of α-PFT structures. (a) Colicin Ia (1CII)[178]. (b)
Cry insecticidal δ-endotoxin (1JI6) [86]. (c) Actinia equina equinatoxin II (1IAZ)[6].
These structures were obtained from the Protein Data Bank (PDB) and rendered using
RASTOP software (RasTop 2.2 By Philippe Valadon, Version 2.2, January 2007).
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even in the presence of the denaturing detergent sodium dodecylsulfate (SDS) at up to
65 ◦C [174]. Because of this, the pores formed by β-PFTs are in many cases more thor-
oughly characterized. For instance, α-hemolysin, anthrax toxin protective antigen and
aerolysin pores are heptamers with diameters of 1.5 to 4.6 nm [159, 127, 179], whereas
the cholesterol-dependent cytolysins can form pores composed of up to 50 monomers
with a diameter up to 30 nm [116, 104, 17].
In contrast, oligomers of α-PFT are far less stable and fall apart when the membranes
are exposed to detergent. The structures of these pores are therefore far less well charac-
terized, and even their subunit stoichiometries are unknown.
In the following section, we will briefly review the current knowledge about the struc-
ture and molecular mechanisms of β-PFTs.
1.3 β-Pore Forming Toxins
β-Pore Forming Toxins share a broadly similar mode of action. All β-PFTs studied
so far are produced and secreted by bacterial cells as stable water-soluble monomers;
upon binding to their target membranes, they start to oligomerize and insert into the cell
membranes and form oligomeric trans-membrane pores. The following subsections will




Figure 1.3: Ribbon representations of β-PFT structures. (a) Aeromonas hydrophila
proaerolysin monomer (1PRE)[125]. (b) Bacillus thuringinesis Cytotoxin (1CBY) . (c)
S. aureus α-hemolysin monomer . These structures were rendered from PDB records
using RASTOP software (RasTop 2.2 By Philippe Valadon, Version 2.2, January 2007).
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1.3.1 Staphylococcus aureus α-Hemolysin
Staphylococcal α-hemolysin is produced as a water-soluble, single-chain polypeptide of
293 amino acid residues, with no cysteine [56]. This toxin can self-assemble on mem-
branes to form a heptameric pore. The mechanism of pore-formation by α-hemolysin has
been extensively studied. The structure of the fully assembled and inserted α-hemolysin
heptamer has been solved, and the monomer structure can be inferred from the crystal
structures of homologous staphylococcal toxins in their monomeric forms [159].
The pore formed by α-hemolysin has a mushroom-shaped structure consisting of a
cap, a rim and a stem domain (Fig. 1.4) [159]. The cap has a diameter of about 10 nm
and is composed of β-sandwich structure. Together with the rim it forms the core of
the protein. The stem or transmembrane domain is constructed of a 14-stranded β-barrel
formed from 7 β-hairpins, with each hairpin contributed by a single monomer [159].
Differences in susceptibility to permeabilization by α-hemolysin have been observed
between different mammalian cells. For example, rabbit erythrocytes are lysed by nanomo-
lar concentrations of the toxin, whereas lysis of human erythrocytes first occurs at 200-
fold higher concentrations; this has been ascribed to the existence of saturable high-
affinity binding sites on the rabbit cells [30, 60, 26]. Some studies have suggested the
existence of a protein receptor for α-hemolysin [171, 123]. Recently, however, Valeva et
al. provided evidence that clustered phosphocholine head groups may serve as sites for
9
Figure 1.4: Staphylococcus aureus α-hemolysin heptameric pore viewed down and per-
pendicular to the pore axis (7AHL) [159]. This structure was rendered from PDB records
using RASTOP software (RasTop 2.2 By Philippe Valadon, Version 2.2, January 2007).
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binding and assembly for α-hemolysin. According to these authors, varying susceptibili-
ties of different cell species toward α-hemolysin is likely due to variations in the number
of phosphocholine head group clusters that are exposed to the extracellular environment
[163].
After initial membrane binding, α-hemolysin first oligomerizes to form a heptameric
non-lytic ‘pre-pore’ complex, which subsequently inserts into the membrane to from the
pore. This pore formation is the result of multiple steps and cooperative process in which
the environment of residues located in the N-terminus changes, as well for the residues
of the rim and the central domain [168, 165, 164, 169].
Studies that were conducted before the X-ray structure of the α-hemolysin pore was
resolved, showed that the a deletion mutations in the N-terminus or within the glycine-
rich stem region (residues 118-142) were arrested in the pre-pore stage [170, 175, 174,
173], indicating that these two regions are important in the pre-pore to pore transi-
tion. Afterwards, the crystal structure of α-hemolysin heptamer showed that the central
glycine-rich stem region from each monomer contributes a two-stranded antiparallel β-
sheet to the β-barrel of the trans-membrane pore, which therefore comprises 14 β-strands
in all.
Based on sequence identity and other similarities, many toxins are considered as ho-
mologous to α-hemolysin. Homologous toxins include the staphylococcal leukocidins,
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Clostridium perfringens β-toxin and Bacillus cereus hemolysin II and cytotoxin K [3].
1.3.2 Anthrax Toxin Protective Antigen (PA)
Bacillus anthracis produces three monomeric proteins that collectively constitute an-
thrax toxin. This A-B toxin is somewhat unusual in having two A components, namely
the lethal factor (LF) and the edema factor(EF). The B component is represented by a
83 kDa pore-forming protein called the ‘protective antigen’. This protein acts as the ve-
hicle for the delivery of LF and EF to the host cells cytosol. Host cell invasion begins
when protective antigen (PA) binds to cellular membrane receptor, is proteolytically ac-
tivated, and oligomerizes to form a ring shaped pre-pore heptamer (Figure1.5). Lethal
factor and edema factor then compete for the binding sites on the PA heptamer, result-
ing in the formation of a complete anthrax toxin complex with 1 to 3 LF and/or EF
molecules per heptamer [32, 101, 102]. The resulting complexes are transported to the
endosome. There, under the influence of the acidic pH, the PA pre-pore is converted
to a mature trans-membrane pore, and LF and EF unfold and traverse the endosomal
membrane across the pore into the cytosol.
The crystallographic structure of monomeric PA shows a long, flat molecule contain-
ing four folding domains (Figure1.6). Domain 1 contains a cleavage site for the protease
furin as well as binding sites for two calcium ions. The calcium ions are important in the
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Figure 1.5: Protective antigen heptamer viewed down and perpendicular to the pore axis
(1TZO) [180]. These structures were rendered from PDB records using RASTOP soft-
ware (RasTop 2.2 By Philippe Valadon, Version 2.2, January 2007).
maintenance of the proper conformation for oligomerization and for ligand binding after
proteolysis [127, 47].
Domain 2 consists of several long β-strands. The main function of this domain is to
form a trans-membrane pore to serve as the portal of entry of EF and LF into the cytosol.
Recently, domain 2 has been shown to participate in binding of PA to the cellular receptor
[79, 145, 11]. Domain 3 is believed to mediate self-association of PA. Mutations in this
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domain strongly inhibit oligomerization of PA [79, 103]. Domain 4 is primarily involved
in binding to cellular receptors, and this domain has little contact with the rest of the
protein [156, 137].
The transition of PA from the pre-pore to trans-membrane pore has been shown to
be dependent on an acidic pH and the specific receptor to which it is bound. Similar
to α-hemolysin, the PA pore is heat stable and SDS-resistant. The pre-pore of PA is
not SDS-resistant; it may be kept in aqueous solution at alkaline pH [84, 93]. When
the environment becomes acidic, the water-soluble heptamer precipitates and becomes
resistant to SDS. This precipitation is probably indicative of the hydrophobic domains
becoming exposed. Moreover, the addition of a non-denaturing detergent such as deoxy-
cholate will also induce transition of the pre-pore to an SDS-resistant heptamer, which
might resemble the conformation of the membrane-inserted pore [93, 94].
1.3.3 Vibrio cholerae Cytolysin
Vibrio cholerae is a Gram-negative bacterium that colonizes the small intestine [144],
and it is the causative agent of the often lethal disease cholera. In addition to cholera
toxin, highly pathogenic strains of V. cholerae produce a pore-forming toxin, known as
V. cholerae cytolysin (VCC).






Figure 1.6: Ribbon representative of Monomeric PA (1ACC) [180]. This structure was
rendered from PDB records using RASTOP software (RasTop 2.2 By Philippe Valadon,
Version 2.2, January 2007).
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lar mass and low sequence identity, the X-ray structure of the VCC pro-toxin, resolved
in 2005, confirmed that VCC belongs to the β-barrel PFTs [117]( Figure 1.7). In ad-
dition, Valeva and colleagues in 2005 have provided further evidence in favor of a β-
barrel organization of the transmembrane pore of VCC using site-specific labeling with
polarity-sensitive fluorophores bound to cysteine mutants within the putative pore region
[167].
VCC is secreted as a pro-toxin ( 80 kDa) that is proteolytically cleaved to yield the
active 65 kDa toxin. The estimated size of the pore formed by VCC is 1.2-1.6 nm [64],
and is composed of heptameric oligomers [58].
Cholesterol in the target cell and liposomal membranes was reported to play an im-
portant role in the assembly of the toxin oligomers needed for pore formation by trigger-
ing oligomerization [64, 65]. In addition, cholesterol was proposed to be the binding site
of VCC on target membrane specially after the observation that VCC binds more effe-
ciently to phosphatidylcholine (PC) liposomes containing cholesterol than to liposomes
composed of PC only [64, 183]. However, it has been reported that VCC can bind to
sphingolipids [184], glycophorin B [181] and glycoproteins [143].
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Figure 1.7: Ribbon representation of VCC pro-toxin (1XEZ) [117].This structure was
rendered from PDB records using RASTOP software (RasTop 2.2 By Philippe Valadon,
Version 2.2, January 2007).
17
1.4 Cholesterol-Dependent Cytolysins
The major part of the research described in this thesis was conducted on pyolysin, which
belongs to the homologous family of the cholesterol dependent cytolysins. Therefore,
this family of toxins will be reviewed separately, despite the fact that it forms a subset of
the β-pore forming toxins.
The cholesterol-dependent cytolysins (CDCs) constitute a large family of pore-forming
toxins that are produced by more than 20 species from the Gram-positive bacterial gen-
era Clostridium, Streptococcus, Listeria, Bacillus, Paenibacillus and Arcanobacterium
(see table 1.1)[3, 162, 51]. Peculiar features of CDCs include their absolute depen-
dence on membrane cholesterol for their cytolytic activity and the formation of very
large pores, which are composed of up to 50 monomers and are up to 30 nm in diameter
[116, 104, 17].
1.4.1 CDC Monomer Structure
In 1997 and 2005, the crystal structures of the two cholesterol-dependent cytolysins per-
fringolysin (PFO) and intermedilysin (ILY) were resolved [138, 128]. As shown in figure
1.8, the monomer structures are rich in β-sheet, have an elongated shape, and are com-
prised of four domains. Domain 1, located at one end of the molecule, has both α-helix
and β-sheet content. Domain 2 is a long curved single layer of anti-parallel β- sheet
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Table 1.1: List of known members of the cholesterol-dependent cytolysins [18].
Organism Toxin Abbreviation
Arcanobacterium pyogenes Pyolysin PLO
Bacillus cereus Cereolysin CLY






C. novyitype A Oedematolysin
C. perfringens Perfringolysin O PFO
C. septicum Septicolysin O
C. tetani Tetanolysin
Listeria ivanovi Ivanolysin O ILO
L. monocytogenes Listeriolysin O LLO
L. seeligeri Seeligerilysin O LSO
Paenibacillus alvei Alveolysin ALY
Streptococcus canis Streptolysin O
S. equisimilis Streptolysin O
S. intermedius Intermedilysin ILY
S. pneumoniae Pneumolysin PLY
S. pyogenes Streptolysin O SLO
S. suis Suilysin SLY
connecting domains 1 and 4. Domain 3 extends from the core β-sheet of domain 1,
and adopts α-β topology with a core consisting of 5 strands of anti parallel β-sheet.
Domain 4 contains the highly conserved tryptophan-rich undecapeptide sequence (ECT-
GLAWEWWR) which appears to mediate the binding of some CDCs to cholesterol-






Figure 1.8: Crystal structure of PFO. A ribbon representation indicating the location of
domains (1PFO). This structure was rendered from PDB records using RASTOP soft-
ware (RasTop 2.2 By Philippe Valadon, Version 2.2, January 2007).
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1.4.2 The Role of Cholesterol in the Activity of CDCs
Traditionally, the role of cholesterol in pore formation was believed to be in the binding
step. This assumption was supported by two main observations: Firstly, the inhibition of
the hemolytic activity of the toxins by incubation with free cholesterol [5, 31, 35, 48, 62,
100, 98, 129, 151, 152, 176], and secondly, the observation of direct binding of CDCs to
pure cholesterol and to liposomes containing cholesterol [67, 71, 115].
Studies with liposomes have shown that the total concentration of cholesterol in lipo-
some membranes required for binding of CDCs is quite high, on the order of 40% by
mole of the total membrane lipid. Interestingly, it has been shown that the transition
from little or no binding to full binding to lipid-cholesterol liposomes occurs within a
narrow range of cholesterol concentration [113].
The dogma that cholesterol is the receptor for CDCs has been re-evaluated in the
current decade, prompted by the discovery that the CDC intermedilysin (ILY) specifically
recognizes human cells; this specificity is based on the ability of ILY to bind to the human
form of the glycosylphosphatidylinositol-anchored protein CD59, indicating that at least
with this toxin cholesterol does not function as the sole receptor [50].
The same authors examined the role of cholesterol in the three CDCs streptolysin
O (SLO), ILY and PFO. It was found that the depletion of cholesterol from erythrocyte
membrane to an extent of 90% abolished the haemolytic activity of those toxins, while
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the binding of SLO and ILY reportedly remained largely unchanged. The extent of PFO
binding decreased tenfold, but binding was still detectable. Nevertheless, the cytolytic
activity of all three toxins was lost, and it was observed that the toxins did oligomerize
but remained arrested at the pre-pore stage. Based on these findings, cholesterol was
proposed to be involved in and essential for membrane insertion of the oligomer rather
than monomer binding [49]. In contrast to these assertions, Nagumune and colleagues
reported that SLO has significant affinity to liposomes consisting of lecithin plus chole-
sterol but not to liposomes lacking cholesterol [107]. In addition, they found that ILY
had no significant affinity to lecithin liposomes with or without cholesterol. Interest-
ingly, ILY showed no specific binding to liposomes of human erythrocyte membrane
lipids [107]. These findings confirm the exceptional binding behavior for ILY but, for
SLO, reaffirm the role of cholesterol in binding to liposomes reported previously for PFO
by Ohno-Iwashita in 1988 [114]. Therefore, consensus on which aspects of toxin activity
are dependent on cholesterol has not yet been reached.
1.4.3 The Pore Forming Mechanism of CDCs
As members of the β-pore forming toxins, CDCs share the same general mechanism of
pore-formation outlined before. In this subsection, I will try to highlight some structural
details associated with this process.
Upon binding to cell membranes, monomers diffuse laterally to initiate oligomeriza-
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tion. Discernible structural rearrangements occur in domain 3 during this process[38],
including the rotation of a loop, comprised of a short β -strand and α-helix, away from
the edge of the D3 core β-sheet to allow oligomerization of the monomers [132].
These oligomerized monomers form what has been termed the pre-pore complex
[53, 52, 155, 61]. These pre-pores consist of toxin molecules in largely the same confor-
mation as before membrane binding [33, 160].
Within the pre-pore oligomers, the main interaction occur through domain 1 and 3
[177, 131, 160]. The subsequent oligomerization of the monomers into pre-pore com-
plexes aligns the twinned D3 trans-membrane β-hairpins (TMH) segments of adjacent
monomers and triggers their insertion into the membrane to form a large trans-membrane
β-barrel as shown in Figure 1.9 [154, 153].
Over the last 30 years , both circular oligomeric rings and incomplete ‘arc’ rings of
CDCs have been observed on membranes using electron miroscopy [99, 31, 16, 112, 150,
121]. This observation, which is an unusual feature not observed with most other toxins,
sparked widespread debate among scientists about the mechanism of assembly of the
CDC oligomeric pore complexes in the membrane bilayer. models have been proposed.
Tweten and his colleagues, found that PFO can indeed assemble into a large oligomeric
complex in the absence of significant insertion of its membrane-spanning beta-hairpins









Figure 1.9: The first step in CDC pore formation mechanism is the binding of the
monomers to the host membrane (A). The monomers oligomerize to form a mem-
brane bound pre-pore (B). Finally a dramatic conformational change occurs to form a
membrane-inserted pore (C) [160].
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complex is obligatory and occurs prior to the insertion of the trans-membrane β-barrel
[59]. The second model was proposed by Palmer and colleagues and suggested that
oligomerization and membrane insertion of a CDC molecule occur concomitantly. Ac-
cording to their model, pore formation is initiated by the formation of of a dimer that im-
mediately inserts into the membrane and serves as a nucleus for further oligomerization.
Further monomers are successively added to the dimer and concomitantly insert into the
membrane, thereby giving rise to a ‘growing’ arc-shaped pore that eventually becomes
the complete, ring-shaped pore [121]. This interpretation was based on the finding that
a mutant that inhibited the oligomerization of native toxin induced the formation of arc-
shaped oligomers in the absence of complete rings, and that these arc-shaped oligomers
formed functional pores of reduced size, indicating that oligomerization does not need to
be complete for insertion to occur. In the third model, proposed by Gilbert, there are two
oligomeric states, pre-pore and pore, and the moment of transition depends on factors
other than the completeness of the oligomeric ring [54]. Furthermore, once the transition
(i.e.,membrane insertion) has occurred, oligomerization ceases. This model appears to
be the only one compatible with all available experimental evidence.
1.4.4 Role of CDCs in Pathogenesis
One of the remarkable features of CDCs is the large size of the pores they form in mam-
malian cell membranes. This aspect has always been somewhat puzzling, since the ap-
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parent cytotoxic effect - membrane permeabilization and cell lysis - can be achieved more
economically with much smaller pores comprised of far fewer monomers, as exemplified
by α- hemolysin.
Despite the progress made in understanding the individual steps that define the cy-
tolytic mechanism of CDCs, the role these toxins play in pathogenesis as pore formers is
not yet completely understood.
However, the effect of pore-forming toxins in pathogenesis is not limited to simple
cell destruction. Like other pore-forming toxins, CDCs are sometimes referred to as
hemolysins due to their lytic activity on red blood cells, which are often used as con-
venient models in experimental studies. However, other cell types are susceptible to
CDCs as well; this includes cells of the immune system. For instance, Streptolysin O
kills human neutrophile granulocytes [41], while pneumolysin exerts its cytotoxicity on
human immune cells (such as macrophages and neutrophils), respiratory endothelial and
epithelial cells [126].
In contrast to erythrocytes, nucleated cells can recover from attack by pore-forming
toxins by a membrane repair mechanism [135]. With immune cells, sub-lethal doses
of CDCs can trigger a cascade of cellular responses such as expression and release of
cytokines by pneumolysin, activation of the components of arachidonic acid cascade in
the host defence cells by pneumolysin [96] and streptolysin O [140], cytokine receptor
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shedding [172] and nitric oxide generation [23]. Such responses very likely contribute to
inflammation and indirect tissue damage in bacterial infections.
In addition to this general mode of action, some CDCs have specific features related
to pathogenicity. Pneumolysin, apart from its direct membrane-damaging action, also
activates complement, which results from its binding to the Fc arm of IgG [97].
Recent studies have revealed that streptolysin O (SLO) translocates the Streptococcus
pyogenes NAD-glycohydrolase into the cytoplasm of host cells, leading to an increase in
cytotoxicity [89, 24, 92]. SLO can therefore be likened to the protective antigen compo-
nent of anthrax toxin; this underscores the close relationship of pore-forming and A-B
toxins. NAD-glycohydrolase translocation requires a special N-terminal domain of SLO
not found in any of the other CDCs, suggesting those toxins do not function in a similar
way.
The most numerous and substantial studies on the role of a CDC in pathogenicity
have been performed on listeriolysin (LLO). This toxin is produced by the intracel-
luar bacterium Listeria monocytogenes. It deviates from other CDCs by its acidic pH
optimum[48]. An acidic environment is encountered by the bacteria inside the phago-
some [10], from which they release themselves into the cytosol by the secretion of LLO.
At later stages of the infection, LLO is used again to break down the cell membranes be-
tween adjacent host cells, facilitating the spreading of bacteria among host cells without
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exposure to extracellular immune mechanisms [46].
1.5 Pyolysin
Pyolysin is a CDC produced by Arcanobacterium pyogenes. This bacterium is Gram-
positive, non-motile, non-spore-forming and rod-shaped. This organism was reclassified
from the genus Actinomyces on the basis of 16S rRNA sequences [134], and it is the most
prevalent pathogen within the Arcanobacterium genus. A. pyogenes grows under aero-
bic and strictly anaerobic conditions, but optimal growth is obtained in a CO2-enriched
atmosphere. All A. pyogenes isolates exhibit beta-haemolysis on agar media containing
bovine or ovine blood [133], even though isolates of porcine origin are generally more
haemolytic [161].
A. pyogenes is an opportunistic pathogen of economically important livestock such as
cattle and swine. This organism is also a common inhabitant of the mucous membranes
of these animals, and is routinely isolated from udders, urogenital, and upper respiratory
tracts of healthy animals [25, 111, 161, 130]. A. pyogenes is also commonly found
associated with the bovine rumen [110] and can be isolated from the porcine stomach
[73].
Since A. pyogenes is a commensal, the source of infection is often autogenous. Al-
though A. pyogenes is capable of acting as a primary pathogen, infection often follows
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a physical or microbial trauma to the mucous membrane, allowing dissemination of the
organism. A. pyogenes is one of the most common opportunistic pathogens of domestic
ruminants and pigs, causing a variety of suppurative infections involving the skin, joints
and organs. These infections include abortion, abscesses, arthritis, endocarditis, mas-
titis, pneumonia, osteomyelitis, uterine infections leading to infertility, and vesiculitis
[161, 85]. Infection is not confined to domestic animals: A. pyogenes is a particularly
versatile pathogen, being able to cause disease in a multitude of different animal species
including antelopes, bison, camels, cats, chickens, deer, dogs, elephants, gazelles, horses,
macaws, reindeer, turkeys and wildebeest. A. pyogenes is an infrequent cause of infec-
tions in humans [45], and these infections are often a result of occupational exposure, as
A. pyogenes is not a part of the human normal flora.
Pyolysin (PLO), is a primary virulence factor of A. pyogenes [19, 34, 9]. PLO is
a haemolysin capable of lysing red blood cells of a variety of animal species, and is
responsible for the characteristic β-haemolysis exhibited by A. pyogenes grown on blood-
containing media [134]. Despite its initial identification as a haemolysin, PLO resembles
most other CDCs in not being confined to any particular cell type.
PLO is produced by all A. pyogenes strains examined to date [19, 34, 9]. It is ex-
pressed primarily in stationary phase cultures [34, 54], where it is detected in culture
supernatant as a 55 kD protein [19, 9].
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PLO has been demonstrated to be a major determinant of virulence in A. pyogenes
infections. An A. pyogenes plo deletion mutant constructed by allelic exchange, was
nonhaemolytic compared to its isogenic wildtype strain, indicating that PLO is the ma-
jor haemolysin produced by A. pyogenes [9]. The plo mutant could be restored to full
virulence by supplying the plo gene in trans, confirming that the reduction in virulence
observed with the plo mutant was due to the defect in PLO production. Significantly
higher doses of the plo mutant were required to establish infection in mice [9]. This
decrease in virulence is similar to the effects of CDC knockouts in other bacteria such as
Streptococcus pneumoniae [14] and Clostridium perfringens [7].
While clearly a member of the CDC family, PLO is unique in several ways. It is the
most divergent member, exhibiting only 31-41% amino acid similarity to other CDCs
(figure 1.10). In addition, PLO, along with the human specific cytolysin intermedilysin
(ILY), have undecapeptide sequences which diverge significantly from the consensus for
this family (table 1.2).
In both PLO and ILY, the otherwise conserved single cysteine residue is substituted
with alanine. This cysteine residue is responsible for the ‘thiol-activated’ nature of most
CDCs, and its lack in PLO or ILY explains why these two toxins are insensitive to thiol
modification [19, 18, 20, 21]. In fact, the replacement of the alanine with cysteine by












Figure 1.10: Phylogenetic analysis of protein sequences showing the relationship be-
tween the cholesterol-dependent cytolysins. Cytolysins are indicated by the name of the
bacterium producing it [2].
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Table 1.2: The conserved undecapeptide sequence of CDCs. Amino acids which do not
match the consensus undecapeptide sequence are in red. Amino acid numbers are given












As with other CDCs, amino acids within the conserved undecapeptide sequence of
PLO, especially the three conserved tryptophan residues, are important for haemolytic
activity and cholesterol binding [20, 21]. However, the divergent undecapeptide se-
quence of PLO appears to be required for its full cytolytic activity, as mutations that
bring the undecapeptide sequence closer to the family’s consensus sequence reduce the
haemolytic activity of PLO [20, 21]. Recent experiments with ILY suggest that this toxin
lacks a specific affinity for cholesterol primarily as a result of its divergent undecapeptide
sequence [107]. While the PLO undecapeptide is more similar to that of ILY than other
CDCs, PLO still retains significant affinity for cholesterol [20, 21]. In addition to the
undecapeptide, two regions at the N-terminus of the protein, amino acids 55-73 and 123-
166, appear to be important for PLO activity, as monoclonal antibodies directed to these
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regions block haemolytic activity [66]. Site-directed mutations within these regions also
result in significant reductions in the haemolytic activity of PLO [66]. These regions
comprise a portion of domain 1 of the PLO molecule, for which no direct function has
been assigned.
While PLO is an important virulence factor for A. pyogenes, the precise role it plays
in pathogenesis is unclear. In addition, while the intraperitoneal mouse model is repre-
sentative of disseminated A. pyogenes infections such as liver abscessation, it may less
accurately reflect other A. pyogenes infections such as mastitis or pneumonia. PLO is
toxic for mouse peritoneal macrophages, the J774A.1 murine macrophage cell line, and
bovine and ovine PMNs [34, 9], and this activity may provide protection for the invad-
ing organism against the host immune response. Consistent with this hypothesis, the
plo mutant is cleared rapidly from infected mice, within 48 h post-challenge, suggesting
that it is overwhelmed by the immune response. In addition, an A. pyogenes strain ex-
pressing a mutant PLO molecule, with a tryptophan to phenylalanine substitution in the
undecapeptide sequence and <0.3 % haemolytic activity, was reduced for virulence to a
similar extent as the PLO knockout mutant [75]. This result suggests that the cytolytic
activity of PLO is important for this toxin to exert its pathogenic effects. In addition to
direct toxicity for immune cells.
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1.6 Streptococcus agalactiae CAMP Factor
1.6.1 Streptococcus agalactiae
Streptococcus agalactiae (S. agalactiae) is a gram positive, non-motile, catalase-negative
bacterium, which can be found as part of the normal flora in respiratory, urogenital and
gastrointestinal tracts of humans. S. agalactiae is also known as Group B streptococcus
(GBS), where the ‘B’ refers to the Lancefield classification. This classification is based
on the so-called C carbohydrate, which is associated with the cell wall and is soluble
in dilute acid; there are 13 types of this carbohydrate, designated A through O, which
can be serologically differentiated. S. agalactiae can be identified by means of cultural
characteristics (such as the tolerance to high salt concentration), pigment production and
biochemical reactions such as the hydrolysis of sodium hippurate, the CAMP test (see
below) and susceptibility to bacitracin [39].
S. agalactiae is an important pathogen in cattle mastitis, resulting in loss of milk pro-
duction [22], and it accounts for a substantial number of cases of invasive infections in
newborn and young infants, pregnant women, and nonpregnant adults who typically have
underlying medical conditions (diabetes mellitus, cancer, liver disease, etc)[147, 8, 148].
Many virulence factors have been found to be associated with S. agalactiae infections.
The best characterized one is the capsular polysaccharide, which prevents deposition of
human opsonic complement component C3b, thus protecting the bacteria from comple-
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ment lysis [36, 37, 91]. In addition to capsular polysaccharides, S.agalctiae produces a
wide range of surface proteins, including the so called α- and β-proteins. The α-proteins
seem to play an important role in the early stages of infection by S.agalactiae [87], while
β-protein (also called Bac protein) was shown to bind to the Fc arm of immunoglobulin
[15, 70, 88, 141, 142].
The lytic phenomenon exhibited by group B streptococci on sheep red blood cells was
first reported by Christie, Atkins and Munch-Petersen in 1944 [28]. These authors found
that GBS induces a distinct zone of complete hemolysis when grown near colonies of
Staphylococcus aureus strain secreting sphinogomyelinase (β-Toxin). This co-hemolytic
effect was called the CAMP reaction after the initials of the last names of its discoverers.
Since then, the CAMP reaction has been used as a diagnostic test for the presumptive
identification of Group B streptococci in clinical isolates.
A 26 kDa extracellular protein produced by Streptococcus agalactiae was found to be
responsible for the CAMP reaction, and therefore was named CAMP factor. The CAMP
factor gene of S. agalactiae encodes a 28 kDa protein with an N-terminal signal peptide
that is cleaved upon secretion. The mature peptide of CAMP factor is a monomeric 26
kDa protein composed of 226 amino acids with a pI of 8.9 [12, 76]. The amino acid
sequence of CAMP factor was determined by Ruhlmann et al. [139]; no cysteine is
present in this protein.
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Like S. agalactiae, some Streptococcus species and Propionibacterium acnes pro-
duce a CAMP reaction on sheep red blood agar plates due to proteins that are closley
homologous to CAMP factor. On the other hand, several other bacteria, such as Rhodod-
coccus equi [44], Listeria monocytogenes, Listeria seeligeri [136], Aeromonas sp.[42],
Actinobacillus pleuropneumoniae [68], also produce CAMP reactions; however, they do
not possess proteins closely homologous to CAMP factor.
Even though CAMP factor has long been presumed to be a virulence factor, a highly
purified CAMP protein was not lethal to rabbits, unlike a partially purified CAMP factor
preparation, which could exert lethal effects when administrated to rabbits and mice
[77, 157].
Lang and Palmer have shown that CAMP factor forms pores of finite size on the sheep
red blood cells membranes (figure 1.11). In addition, further studies with liposomes
confirm that the process of CAMP factor pore formation is highly cooperative, supporting
an oligomeric nature of the membrane lesion [82].
GPI-anchored proteins act as cell surface receptors for CAMP factor, and the binding
site appears to be located in the glycan core of the GPI anchor moiety [83].
In addition to its pore-forming activity, CAMP factor was reported to bind to the Fc
fragment of IgG and IgM; therefore, it was called Protein B [77], in analogy to Staphy-
lococcus areus protein A. The reported Fc binding property of CAMP factor suggested a
36
Figure 1.11: Electron microscopy of the pore formed by CAMP factor on sheep red cell
membranes. Magnification varies among panels A - D as indicated by the scale bars. this
image obtained from Lang and Palmer 2003 [82]
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possible role of CAMP factor in resistance to phagocytosis.
1.7 Research Objectives
The work described in this thesis consists of two parts. The first part was conducted on
pyolysin, while the second part concerns CAMP factor.
In the first part, the main objective was to characterize the role of lipids other than
cholesterol in the activity of PLO; such possible roles had not been thoroughly studied
before. This interest came from our preliminary observation that treating red blood cells
with sphingomyelinase, which converts sphingomyelin to ceramide, will greatly enhance
the susceptibility of erythrocytes to PLO. This work is discussed in detail in chapter 3.
Our preliminary experiments on the lipid specificity of PLO with model membranes
led us to consider the possibility that pyolysin might also oligomerize in solution, which
we found indeed to be the case. The functional characterization of PLO oligomers
formed in solution became the other main focus of this study and is described in de-
tails in chapter 2.
In the second part, our original objective was to examine the possibility that the re-
ported binding of Streptococcus agalactiae CAMP factor to the Fc fragment of IgG [77]
might inhibit the activation of complement (as is the case with staphylococcal protein
A), and if applicable, to characterize the region of the CAMP factor molecule responsi-
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ble for such an effect. As it turned out, no such inhibitory effect occurred, which led us










Pyolysin (PLO) is an important virulence factor of A. pyogenes [19, 34, 74]). PLO be-
longs to the family of cholesterol-dependent cytolysins (CDCs), which comprises toxins
produced by more than twenty species of gram-positive bacteria. Within this family,
PLO is unique in several ways. It is the most divergent member, exhibiting only 31-41%
amino acid identity to other CDCs. Also, unlike most other CDCs, it is insensitive to
either reducing agents or thiol-blocking agents [19, 18, 20] . This is due to the lack of
a cysteine residue that is conserved in all other CDCs but one, the sole other exception
being Streptococcus intermedius intermedilysin (ILY; [108]). For additional detail see
section 1.5.
The mechanism by which CDCs form pores was reviewed in Chapter 1. Briefly, All
CDCs are secreted as soluble monomeric molecules. Upon binding to target membranes,
they oligomerize to form oligomeric pre-pores, which then insert into the lipid bilayer to
form the final trans-membrane pores. Depending on whether or not oligomerization was
completed at the time of insertion, pores may be ring-shaped or arc-shaped; in the latter
case, the opposite side of the pore is lined by a free edge of the lipid membrane [121].
While efficient oligomerization of CDCs requires the presence of membranes, it was
previously reported that pneumolysin, which is produced by Streptococcus pneumoniae,
self-associates in solution to form oligomeric structures similar in size and shape to those
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that appear on the membrane coincident with pore formation [51, 53]. Preliminary exper-
iments with PLO and model membranes led us to consider the possibility that pyolysin
might also oligomerize in solution. In this report, we present evidence that this is in-
deed the case. The oligomers formed appear to be of a fairly homogenous size, which
is much smaller than the typical size of membrane-derived oligomers. The solution-
derived oligomers retain the ability to assemble into larger oligomers on membranes
and thereby permeabilize them, but the pores thus formed do show some structural and
functional differences from those formed by monomeric PLO. The findings of this study
have significant implications for the interaction of CDCs with lipid membranes and the
mechanism of pore formation. 1
1This work has been submitted for publication.
Guenter Scholz, Stephen Billington, Naghmeh Sarraf and Michael Palmer are co-authors for this work.
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2.2 Materials and Methods
2.2.1 Production and Purification of Histidine-tagged PLO (His-PLO)
Cultures (1000 ml) of E. coli BL 21 carrying the pTrcHis B plasmid with wild type [20]
PLO or N90C mutant PLO were grown in Luria-Bertani (LB) broth (Bioshop, Burling-
ton, Ontario) with ampicillin (100 µg/ml) at 37◦C. Once the OD600 had reached a value
of 0.6, protein expression was induced with 1.0 mM IPTG, and incubation continued for
another 3 h. The cells were then shaken overnight at 25◦C and 150 rpm. Cells were
harvested by centrifugation at 5000 x g for 10 mins and the cell pellet was resuspended
in column binding buffer (20 mM Tris/HCl, 150 mM NaCl, 10 mM imidazole, pH 8.0).
The cells were lysed using an emulsifier (Avestin Emulsiflex-C5) at 17,500 psi and the
insoluble material was removed by centrifugation at 12000 xg for 30 mins. His-PLO
was purified from the soluble fraction by metal-chelating chromatography on Ni-NTA
agarose (Novagen, Oakville, Ontario), using a linear gradient of imidazole (10 mM - 450
mM) in binding buffer for elution.
2.2.2 Cysteine-specific Labeling of Mutant N90C
The single cysteine mutant N90C was constructed by site-directed mutagenesis as de-
scribed in [63] and confirmed by DNA sequencing (Mobix lab, Hamilton, ON). The
mutant protein was purified by metal-chelating chromatography as describe above, and
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2 mg/ml of PLO with the unique cysteine residues were labeled with a mixture of
fluorescein-5- maleimide (Invitrogen) and tetramethylrhodamine-5-maleimide (Sigma)
(1:3) in Tris-buffered saline (TBS; pH 7.5). The absolute concentrations for fluorescein-
5- maleimide and tetramethylrhodamine-5-maleimide were 125µM and 375µM, respec-
tively. Incubations were for 30 min at room temperature. Excess label was then removed
by gel filtration on a PD10 column equilibrated with TBS, and the monomers and solu-
tion derived oligomers separated by size exclusion chromatography as described below.
2.2.3 Size Exclusion Chromatography
Size exclusion chromatography was performed using a Superdex 200 column (40cm x
0.8cm), equilibrated with PBS, on an AKTApurifier chromatography system (GE Health-
care, Baie d’Urfe, QC, Canada). The flow rate was maintained at 0.3 ml.min−1, and the
elution profile was monitored by online measurement of the A280. The eluate was col-
lected in fractions of 0.3 ml and analyzed by SDS-PAGE.
2.2.4 Lysis of Red Blood Cells
Venous blood was obtained from volunteers, and the red blood cells were washed five
times in hemolysis buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) by centrifugation.
The erythrocytes were then resuspended in hemolysis buffer to 0.5% (v/v). 20 µl of
cell suspension was added to the wells of a microtiter plate containing serial dilutions of
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PLO in 180 µl of the former buffer. Hemolysis was measured by the decrease in turbid-
ity (A650) using a 96-well plate reader (Spectramax 190, Molecular Devices, Sunnyvale,
CA). Alternatively, un-lysed cells and cell membranes were pelleted by centrifugation,
and the absorbance of hemoglobin released into the supernatant (A540) was measured. A
sample of red blood cells incubated in the absence of PLO was used as a blank, and read-
ings from cells osmotically lysed in 10 mM phosphate buffer, pH.7.4 were considered as
100% lysis.
2.2.5 Marker Release Experiments
Washed, packed human red blood cells were osmotically lysed on ice with 10 vol. of
10 mM sodium phosphate buffer (pH 7.4), and the membranes repeatedly washed by
centrifugation (4◦C at 15 000 x g for 3 min) in the same buffer. After a final wash
with 16 mM Na-phophate/150 mM NaCl (PBS), the membrane ghosts were resuspended
in PBS containing 0.25 mg/ml fluorescein isothiocyanate-dextran (Sigma; average mol.
weights, 4, 75, 250 or 2000 kDa, respectively) and incubated at 37◦C for 45 min. The re-
sealed ghosts were washed with PBS by centrifugation four times, incubated for 30 min
on ice, and washed again. The pellet was then resuspended in 20 volumes of the same
buffer. Serial twofold dilutions were prepared from 200 µg/ml of monomeric PLO or of
solution-derived oligomers in PBS. To each dilution (100 µl), 50 µl of the marker-laden
ghost suspension was added, followed by incubation at 37◦C for 30 min. The samples
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were then centrifuged at 12,000 x g for 2 min, and the supernatants were diluted into 3
ml of 10 mM Tris/50 mM NaCl/0.2% SDS (pH 8.0) and analyzed fluorimetrically. The
percentage of marker released was obtained by comparison with a Triton-lysed refer-
ence; spontaneous leakage was assayed on a parallel sample incubated without toxin and
subtracted.
2.2.6 Electron Microscopy
Red blood cells were incubated and lysed with 50 µg/ml PLO, and the membranes were
collected by centrifugation. The membranes were washed three times with 5 mM HEPES
buffer (pH 7.4) and mounted onto carbon-coated grids (Formvar/copper, 200 mesh; Mari-
vac Ltd., St.Laurent, QU) followed by negative staining with sodium phosphotungstate
(2% w/v, pH 7.4) for 5 s. Membranes were then examined in a LEO 912 AB Omega
electron microscope operated at 100 kV.
For solution-derived oligomers without membranes, samples (7 µl) were placed on
400-mesh carbon coated formvar copper grids (Marivac Ltd., St.Laurent, QU). After
several minutes the grids were dried, washed three times with 10 l of water and stained for
15 second using saturated uranyl acetate (pH. 4.5). Specimens were viewed with a Philips
CM20 electron microscope (Philips Electronics Ltd., Guildford, UK) at an accelerating
voltage of 200 kV. Images were digitized using a Gatan 679 slow-scan CCD camera and
analyzed using DIGITALMICROGRAPH software (version 2.1, Gatan inc., Pleasanton,
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CA).
2.2.7 Preparation of Liposomes
All lipids were purchased from Avanti Lipids (Alabaster, AL). The lipids, dissolved in
chloroform, were mixed in various molar ratios (see ”Results”), dried down under ni-
trogen in a round-bottom flask, and then dried under vacuum for an additional 3 h to
remove the residual solvent. The dried lipids were hydrated at room temperature for 1 h
in 1 ml of phosphate buffer saline (PBS), pH.7.3. The lipid suspension was sized down
to unilamellar liposomes using a liposome extruder (Northern Lipids, Vancouver, British
Columbia, Canada) by extrusion 10 times through a polycarbonate membrane with a
100-nm pore size.
2.2.8 Preparation of Erythrocyte Membranes
Human red blood cells were osmotically lysed in 5 mM phosphate buffer (pH 7.3) and
the membrane were pelleted and repeatedly washed until they appeared white. The last
wash was conducted using PBS (pH 7.3).
2.2.9 Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were obtained in a Jasco J-715 CD spectropolarimeter
using J-715 analysis software. Samples were measured in a 1 mm quartz cuvette (Hellma,
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Concord, Ontario, Canada) kept at 25◦C. Samples consisted of 100 µg monomeric or
SDO PLO alone or PLO with DMPC liposomes or 1:1 DMPC:cholesterol liposomes
and incubated for 30 minutes at 37◦C. Spectra were recorded over a 190-250 nm range
with a 1.0 nm bandwidth, 0.2 nm resolution, 100 mdeg sensitivity at a 0.125 s response,
and a rate of 100 nm/min with a total of 25 accumulations. Spectra for liposomes alone
were obtained as references and subtracted from the spectra obtained of the toxin in the
presence of liposomes.
2.2.10 Electrophoresis
SDS-PAGE was performed according to Laemmli [80], using polyacrylamide concentra-
tions of 4% in the stacking gels and of 12% in the resolving gels. Gels were stained with
Coomassie blue.
2.2.11 Protein Assay
PLO concentrations were determined using the absorbance at 280 nm and a calculated
extinction coefficient of 68,480 M−1.cm−1. The extinction coefficient was calculated
from the amino acid composition according to Pace et.al [118].
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2.2.12 Spectrofluorimetry
Steady-state fluorescence measurements were taken using a PTI QuantaMaster spec-
trofluorimeter. The excitation and emission for fluorescein wavelengths were 492 and
520 nm, respectively. Time-resolved measurements were performed in a FT-100 compact
fluorescence lifetime spectrometer (PicoQuant, Berlin, Germany), using a LDH-P-C-470
LED laser light source. Fluorescein emission was isolated using a 520 5 nm bandpass
filter (Andover Corporation, NH, USA). Decays were fitted using FluoFit software (Pi-
coQuant), allowing for two fluorescence lifetime components, from which the average
lifetime < τ > was calculated according to the formula
< τ > = Σαiτi/Σαi
where α represents the intensity contribution of a given lifetime component at t=0.
Where necessary, a third component with a lifetime of 50 ps was allowed for to accom-
modate light scattering; this component was excluded from the lifetime calculation. The
fit residuals were evenly distributed, and the χ2 values below 1.3 in all cases.
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2.3 Results
2.3.1 Spontaneous Oligomerization of PLO in Solution
. Oligomers were present in cell lysates of E. coli cells recombinantly expressing his-
tagged PLO. Figure 2.1 shows the elution profile of a sample of PLO as obtained from
E.coli lysate by metal-chelating chromatography, resolved on a Superdex 200 column.
Ahead of the main peak, which corresponds to the monomer with a molecular weight
of 57 kDa, there is a well-defined peak containing oligomeric PLO. The elution volume
of this peak corresponds to an apparent molecular weight of approximately 350 kDa,
which indicates that the oligomeric species contains approximately 6 monomer subunits.
Both peaks, when re-chromatographed immediately after isolation, where stable, i.e.,they
eluted as single, symmetrical peaks at their previous positions (Figure 2.2).
Incubation of isolated monomers (2 mg/ml) for 12 hours at 20 ◦C resulted in the for-
mation of some more oligomer, as shown in Figure 2.3. The extent of oligomerization
observed in vitro increased with the monomer concentration but was not detectably af-
fected by variation of pH (pH 5-10) or salt concentration (0-0.5M NaCl; data not shown).
Since at pH 5 the histidine residues in the purification tag will be protonated, it seems
unlikely that the his-tag is responsible for oligomerization. This conclusion is also sup-
ported by the previous observations that oligomers of similar size form with pneumolysin
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Figure 2.1: Size exclusion chromatography elution profiles of 2 mg/ml PLO, resolved on
a Superdex 200 column, as purified from E. coli cultures by metal-chelating chromatog-
raphy. Ahead of the main peak, which corresponds to the monomer, there is a peak
representing the solution-derived oligomer. The peak positions of apoferritin (443kDa)
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Figure 2.2: Size exclusion chromatography elution profiles of rechromatographed
monomers and oligomers immediately after isolation, resolved on a Superdex 200 col-




















Figure 2.3: Size exclusion chromatography elution profiles of 2 mg/ml monomeric PLO
(isolated by gel filtration) after incubation at 20◦C for 12 hours.
other CDC (perfringolysin O) in solution [158]. The extent of oligomerization obtained
with purified monomer in vitro was significantly smaller than that observed with the un-
fractionated protein extracted from E.coli. This may be related to the higher monomer
concentration present in the bacterial cytoplasm (5mg/ml).
The size of the oligomer did not change significantly between different preparations
or experiments. When a PLO sample that had not been subjected to gel filtration was

















Figure 2.4: Size exclusion chromatography elution profiles of unfractionated PLO was
concentrated to 10 mg/ml PLO and incubated for 4 hours at 37◦C before gel filtration.
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of higher molecular weight were apparent in low abundance, but the position of the
major oligomer peak was unchanged (Figure 2.4). This suggests that the solution-derived
oligomers do not grow by successive apposition of further monomers; rather, it appears
that larger oligomeric species may form from the aggregation of small oligomers. In
all further experiments, the oligomers used were obtained as described in the legend to
Figure 2.1; this preparation will be referred to as ‘solution-derived oligomers’, or SDO
for short.
2.3.2 Conformation of the Subunits in Solution-Derived
Oligomers
While the toxin monomers undergo local conformational changes as they bind to mem-
branes and assemble into pre-pores [160] , the major conformational change is associ-
ated with the final event of co-operative membrane insertion of the oligomer [160]. As
evident in Figure 2.5, this latter change is reflected in a difference between CD spec-
tra of monomeric PLO and membrane-associated oligomers obtained by incubation with
cholesterol-containing liposomes [109]. On the other hand, the CD-spectrum of solution-
derived oligomers closely resembles that of monomeric PLO in buffer or after incuba-
tion with cholesterol-free liposomes. This indicates that, in the SDO, the conformational
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Figure 2.5: Far-UV CD spectra of SDO, monomers, monomers in the presence of chole-
sterol liposomes (1:1, cholesterol and PC) and PC liposomes. In all samples, the toxin




























Figure 2.6: Hemolysis of human erythrocytes by monomeric and oligomeric PLO. Red
blood cells (0.5% by volume) were exposed to various concentrations of monomeric
and oligomeric PLO. Hemolysis was assayed by measuring the OD540 of hemoglobin
released into the supernatant.
2.3.3 Hemolytic Activity of Solution-Derived PLO Oligomers
To test the activity of SDO, a hemolysis assay was performed (Figure 2.6). Surprisingly,
it was found that SDO exhibit hemolytic activity, even though their hemolytic titer was
approximately four times lower than that of the monomers, and hemolysis was slower





















Figure 2.7: Hemolysis kinetics of monomeric and oligomeric PLO. Human erythrocytes
(0.5% by volume) were exposed to 25 µg/ml of monomeric and oligomeric PLO, re-
spectively, and the time course of hemolysis was measured by the decrease in turbidity
(OD650).
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2.3.4 Electron Microscopy of Pores Formed by Solution-Derived Oli-
gomers
With approximately 6 subunits, the SDO are far smaller than the typical, mostly ring-
shaped CDC oligomers that form on susceptible cell membranes and which contain ap-
proximately 50 subunits [119]. With pyolysin, the membrane-associated oligomers had
not been characterized before. Therefore, the observation of hemolytic activity associ-
ated with the small, solution-derived oligomers raised the question whether or not the
pores formed by PLO are of the same size as those of other CDC. Figure 2.8a shows
oligomeric pores on red cell membranes that were incubated with monomeric PLO. Most
oligomers are complete circles, with diameters of approximately 30 nm; a few incom-
plete, arc-shaped oligomers also present. This pattern very much resembles that observed
previously with other CDC [112, 121, 99, 31, 16, 150]; therefore, the oligomers that form
from monomers on membranes are far larger than the solution-derived oligomers.
The question then arose whether the SDO form pores individually, or whether they
give rise to larger structures in order to form pores. Figure 2.8b shows pores formed by
incubation of red cell membranes with solution-derived oligomers. In this sample, most
oligomers are incomplete and arc-shaped; a few apparently complete rings are seen as
well. At the same time, most of the arcs approach or slightly exceed half-circle size. This
size corresponds to approximately 20-25 subunits; therefore, the observed oligomers
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A.                                                       B.
Figure 2.8: Electron microscopy of oligomeric forms of PLO. (a) Sheep red blood cell
membranes, incubated with 80 µg/ml of monomeric PLO. (b) Sheep red blood cell mem-
branes, incubated with 80 µg/ml of solution-derived oligomers.
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cannot correspond directly to single SDO but rather must have arisen by association of
several of the latter.
Figure 2.9 shows SDO that have not been incubated with membranes. They appear
as oblong structures with a length mostly between 7 and 15 nm (see arrows.). Assuming
a distance between two neighboring subunits in an oligomer of 2.5 nm [33], this corre-
sponds to 3-6 subunits per oligomer. This size is definitely much smaller than that of
oligomers observed on membranes, which further supports the idea that several solution-
derived oligomers jointly give rise to one larger pore upon binding to target membranes.
2.3.5 Mechanism of Pore-Formation by Solution-Derived Oligomers
The observed formation of one large pore from several SDO might occur by way of
directly merging several SDO into one membrane-associated oligomer. Alternatively, it
is also conceivable that SDO, though stable in buffer, would dissociate upon membrane
binding into monomers, which would then assemble into oligomers in the usual way.
To distinguish between these possibilities, we employed a hemolytically active single
cysteine mutant of pyolysin (N90C) that was labeled with a mixture of fluorescein and
rhodamine. These two labels constitute an efficient pair for fluorescence energy transfer;
they were attached to the unique cysteine residue of the mutant protein, so that each
monomer in an SDO carried either fluorescein or rhodamine, but not both. Table 2.1
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20 nm
Figure 2.9: Electron microscopy of solution-derived oligomers in the absence of red
blood cells.
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lists the fluorescence lifetimes of labeled SDO in various experiments, as well as those
of monomeric control samples. The average fluorescence lifetime of fluorescein in a
monomer sample is 3.4 ns; it drops to 2.5 ns upon interaction with membranes, which is
due to FRET between fluorescein- and rhodamine-labeled subunits drawing near within
mixed oligomers. Inclusion of unlabelled monomers in excess over the labeled ones
will prevent the two labels from getting close within hybrid oligomers, and accordingly









































































































































































































































































































































































































































The fluorescence lifetime of SDO is similar to that of the membrane-derived oligo-
mers; it changes very little upon interaction with membranes in the presence of unla-
beled monomers in excess. If the SDO had dispersed into monomers, these should have
then formed hybrid oligomers with unlabeled monomers, and the fluorescence lifetime
should have increased to a value similar to that observed before with labeled and unla-
beled monomers on membranes. The fact that this did not happen indicates that the SDO
do not dissociate. Therefore, SDO may interact directly with one another to form larger
oligomers, which then give rise to trans-membrane pores.
2.3.6 Functional Size of Pores Formed by Solution-Derived Oligo-
mers
Previous experiments with an oligomerization-impaired mutant of streptolysin O (an-
other CDC with homology to PLO) have demonstrated that incomplete, arc-shaped oli-
gomers may form pores of reduced functional diameter[121]; however, this point has
been contested [155]. We therefore asked whether or not the higher abundance of in-
complete, arc-shaped pores observed with SDO resulted in a reduced functional pore
diameter. To answer this question, dextran marker release assays were performed, us-
ing fluorescein-labeled dextrans of different molecular weights. Figure 2.10a shows that
dextrans 250 and 2000 (with average molecular weights of 250 and 2000 kDa, respec-
tively) are released to the same extent if the membranes are exposed to monomeric PLO;
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the same also applies for smaller species such as dextran 4 and 75 kDa (data not shown).
This suggests that essentially all toxin pores are permeable for the largest species. Dex-
tran 2000 has an estimated molecular diameter of 58 nm [149], which exceeds the diam-
eter of the PLO pores. The fact that dextran 2000 is released nevertheless is in line with
previous findings that dextran and other linear polymers can permeate across pores of
smaller diameter by partial uncoiling and ‘reptation’, i.e.,a snake-like wriggling action
that results from Brownian motion [106]. With pores formed by solution-derived oligo-
mers, release of dextrans also proceeded in parallel up to a molecular weight of 250 kDa
(data not shown). However, dextran 2000 was released to a lesser extent than dextran 250
at all toxin concentrations tested (Figure 2.10b). Therefore, the incomplete, arc-shaped
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A.                                                              B.
Figure 2.10: Release of FITC-dextran 250 and 2000 from human erythrocyte ghosts by
monomeric PLO and by solution-derived oligomers. Ghosts were incubated for 30 min
with twofold serial dilutions of (a) monomeric PLO and (b) solution-derived oligomers;
the concentration in the first well was 133 g/ml in either case. The percentage of marker
released was obtained by fluorescence as described in Materials and Methods.
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2.4 Discussion
While CDCs require cholesterol (normally as part of lipid membranes) for efficient
oligomerization, the slow formation of oligomers in solution has been reported before
for one such toxin (pneumolysin) [51, 53, 158]. Analytical ultracentrifugation showed
that the size of these oligomers ranges from dimers to hexamers [158]. In the present
study, we show that PLO, too, may form oligomers in solution. While the exact subunit
stoichiometry - or distribution thereof - of this species was not determined, size exclusion
chromatography indicates a number of approximately 6 subunits, whereas EM suggests
some degree of variation, which is in line with the previous findings on pneumolysin.
A novel finding of this study is the observation of hemolytic activity in the solution-
derived oligomers. Frequently, oligomerization of pore-forming proteins in solution is
associated with loss of activity. This has been observed with prematurely oligomerizing
mutants of Staphylococcus aureus α-hemolysin [169]; similarly, the lack of hemolytic
activity in complement membrane attack complexes that form prematurely in solution is
the underlying principle of the complement-fixation assay [78].
With CDCs and other pore-forming toxins, it is commonly assumed that the unit of
toxin polymerization on membranes is the toxin monomer itself. The observation of
hemolytic activity in the SDO shows that this need not necessarily be the case - larger
oligomers can assemble from smaller ones. One might therefore consider the possibility
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that, not only in solution but also on membranes, small oligomers may form first and then
function as the unit of polymerization in the formation of larger oligomers. However, the
time course of oligomerization of streptolysin O on membranes [122] supports a mech-
anism of oligomerization that is directly driven by monomers. In addition, a difference
in the mechanism of pore-formation by monomers and SDO is suggested by the pre-
dominance of incomplete, arc-shaped oligomers on membranes exposed to SDO. How
can this latter observation be understood? With streptolysin O, oligomerization follows
a two-step nucleation-propagation pattern. The rate-limiting step is nucleation; the rela-
tive rapidity of propagation ensures that most oligomers will complete a short time after
initiation. Therefore, at any time, the number of incomplete oligomers competing for the
limited pool of monomers is low [122]. In contrast, with SDO, there is no distinction be-
tween monomeric and oligomeric reactants, and thus there may not be much of a kinetic
difference between nucleation and propagation. Furthermore, the assembly of complete
rings may be sterically hindered, as two arc-shaped intermediates each spanning more
than a half-circle will no longer be able to combine into a full one.
The observation that the pores formed by SDO have a lower effective diameter con-
firms the previous assertion that incomplete, arc-shaped oligomers can indeed form pores
[121]. It does not, however, imply anything about the temporal coordination of oligomer-
ization and membrane insertion; while the study cited proposed a simultaneous progres-
sion of both, it has since been shown that oligomerization does indeed precede mem-
69
brane insertion, resulting in the formation of a transient oligomeric ‘pre-pore’ complex
[155, 61].
Incubation of PLO at various concentrations and for different lengths of time resulted
in different yields of SDO. In contrast, the size was not detectably affected, indicating
that the SDO is at least meta-stable and does not readily grow by the addition of fur-
ther monomers. Why is this? One hypothesis would be that the SDO assume some
closed shape, e.g.,ring shape (Figure 2.11a) that precludes any addition of further sub-
units. However, this does not fit with the extended appearance of the SDO observed by
EM, or with the fact that SDO can readily react with each other on membranes.
The only other possibility appears to be that SDO undergo some conformational
change that prevents them from reacting with monomers, without preventing them from
reacting with each other (Figure 2.11b and c; in solution, the reaction between SDO may
be slow because of their low concentration). While ‘global’ spectroscopic methods such
as circular dichroism do not provide evidence of any conformational change accompa-
nying the formation of SDO, differences observed in the interaction of monomeric PLO
and SDO with membrane lipids suggests that some conformational differences do indeed
exist(see chapter 3). The assumption of a conformational transition raises the question
how it may be kinetically related to the progress of oligomerization.





Figure 2.11: Hypothetical explanations for the limited size of oligomers forming in solu-
tion: The addition of further monomers may be prevented either by closed geometry of
the oligomer (a) or by a conformational change that occurs at a certain stage of oligomer-
ization (b). The latter would still permit the association of oligomers with each other (c),
as observed at higher concentration in solution and on membranes.
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ceases at a size of approximately 6 subunits. It was proposed that the premature termina-
tion of oligomerization is due to a conformational transition of the SDO. The probability
(or kinetic rate of this change) may be related to the size of the SDO in various ways:
It may be cooperative in nature and therefore require a minimum size of the oligomer.
Once this minimum size is reached, the rate of the conformational change may or may
not change with the number of oligomer subunits. If we assume that the conformational
change may originate in a single subunit or a small number of cooperating subunits and
then spread in a domino-like fashion among the residual subunits - as has been observed
with oligomers of Staphylococcus aureus α-hemolysin, [166] - the rate of the conforma-
tional change will be approximately proportional to the size of the oligomer.
Figure 2.12 shows numerical simulations based on the assumptions that:
1. Oligomerization starts with a nucleation event, which is of second order for the
monomers (as with the membrane-dependent oligomerization of streptolysin O
[122],
2. The nucleus grows by ‘propagation’, i.e.,successive addition of further monomers,
which is of first order for both the monomers and the nuclei,
3. The rate of the conformational change of the SDO that terminates its growth is


















Figure 2.12: Hypothetical oligomer size distributions for the cases of a size-independent
and a size-proportional rate constant, respectively, of the conformational change that
results in the termination of oligomer propagation.
The constraints of the model do not suffice to determine the rate constants of all reac-
tions: As long as the rate of nucleation is low, the resulting oligomer size distribution is
determined by the ratio of the rate constants for propagation and conformational change.
A program was written by Dr. Palmer that systematically varied this ratio, using a gradi-
ent descent method so as to make the hexamer the most abundant oligomer species. The
simulation was stopped once the monomer level had dropped to below 80% of the total.
The results of these calculations are shown in Figure 2.12.
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With the assumption of a size-dependent rate constant, the oligomer size distribution
peak is fairly sharp, which seems to be in agreement with the elution profile (it would be
sharper yet if two or more adjacent subunits were required to trigger the conformational
change; not shown). In contrast, with a size-independent rate constant of the conforma-
tional change, the resulting distribution is much broader. Considering that oligomers with
more than 12 subunits should be eluted in the exclusion volume of the Superdex column,
this simulation does not match the experimental chromatographic elution profile.
The model predicts that the maximum of the oligomer size distribution should change
with the square root of the monomer concentration; whether or not this holds true is
difficult to determine experimentally, since at low toxin concentrations oligomerization
proceeds very slowly.
In sum, our study shows that PLO forms small oligomers in solution, the size of
which may be limited by an internal conformational change that terminates oligomer-
ization. These small oligomers retain hemolytic activity and are capable of assembling
into larger ones on membranes. The oligomers thus formed remain incomplete and arc-
shaped, and they give rise to pores of smaller functional size than the ring-shaped, com-
plete ones that result from the incubation of monomeric PLO with membranes. This









Arcanobacterium pyogenes secretes a pore-forming toxin, pyolysin (PLO), which is a
member of the family of cholesterol-dependent cytolysins (CDC) [19, 74, 34, 73, 72].
These toxins exhibit two characteristic features: the formation of very large pores, and
their dependence on the presence of cholesterol in their target membranes [18, 119, 162].
Membrane binding of the CDC toxins involves a conserved region close to the C-
terminus that contains three closely spaced tryptophan residues. With the exception of
only two toxins (PLO and intermedilysin [19, 108]), this undecapeptide sequence also
contains a unique cysteine residue, the modification of which renders the toxin molecule
inactive. The fact that some such modifications may be reverted by thiol reagents, and
that the toxins may thereby be reactivated, has earned the toxin family the alternative
name of ‘thiol-activated toxins’.
Within the CDC family, PLO is the most divergent member, exhibiting only 31-41%
amino acid similarity to the other ones. It is also one of the two only toxins lacking the
conserved cysteine, and the three tryptophan residues within its undecapeptide region de-
viate from the otherwise perfectly conserved spacing [19, 18, 20]. The divergence within
the putative membrane-binding region prompted us to examine the lipid specificity of
the pyolysin-membrane interaction. We report here that pyolysin is able to permeabilize
liposome membranes that contain no cholesterol or any other sterol.
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In chapter 2. we discussed our findings that pyolysin is subject to a slow oligomer-
ization in solution. The process of oligomerization and the behavior of the oligomers
thus formed on cell membranes are the subject of chapter 2. Here, we report that the
lipid specificity of monomeric toxin differs from that of the solution-derived oligomers,
and we discuss the implication of this finding for the role of cholesterol in the different
stages of toxin action.
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3.2 Materials and Methods
3.2.1 Production and Purification of Histidine-tagged PLO
Pyolysin (PLO) was purified as described before in chapter 2 (subsection 2.2.1), and the
solution derived oligomers were obtained using superdex 200 coloumn as described in
subsection 2.2.3.
3.2.2 Lysis of Red Blood Cells
Hemolysis assay was conducted as described before in subsection 2.2.4.
For Sphingomyelinase treatment, 0.5 % washed red blood cells were incubated for
30 minutes at room temperature with 50 milliunits/ml sphingomyelinase from S. aureus
(EC 3.1.4.12 , Sigma) in the hemolysis buffer in the presence of 10 mM MgCl2.
3.2.3 Preparation of Liposomes
All lipids were purchased from Avanti Lipids (Alabaster, AL). The lipids, dissolved in
chloroform, were mixed in various molar ratios (see ”Results”), dried down under nitro-
gen in a round-bottom flask, and then dried under vacuum for an additional 3 h to remove
the residual solvent. The dried lipids were hydrated at room temperature for 1 h in 1 ml of
phosphate buffer saline (PBS), pH.7.3 containing 50 mM calcein. The lipid suspension
was sized down to unilamellar liposomes using a liposome extruder (Northern Lipids,
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Vancouver, British Columbia, Canada) by extrusion 10 times through a polycarbonate
membrane with a 100-nm pore size.
For ceramide-containing liposomes, the suspension was warmed to 45◦C during hy-
dration. The suspension was frozen at -20◦C and thawed at room temperature for several
times. The lipid suspension was sized down to unilamellar liposomes using a liposome
extruder (Northern Lipids, Vancouver, British Columbia, Canada) by extrusion 10 times
through a polycarbonate membrane with a 100-nm pore size. The extruder was ther-
mostatted to 45◦C to facilitate processing of the ceramide-containing liposomes. The
non-entrapped calcein was removed by gel filtration on Agarose 6-B pre-equilibrated
with HBS.
3.2.4 Calcein Release Assay
The liposomes with entrapped calcein were mixed with various amounts of PLO in 10
mM Tris-HCl, 150 mM NaCl, pH 7.4 buffer. After incubation at 37◦C for 10 min,
the samples were diluted with the same buffer, and calcein fluorescence intensity was
measured immediately (excitation, 480 nm; emission, 520 nm). The fraction of calcein
released was calculated by deducting the fluorescence intensity of a control sample incu-
bated without PLO. 100% release was obtained from a liposome sample lysed by 6 mM
sodium deoxycholate (pH. 8.0).
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3.2.5 Electron Microscopy
Red blood cells ,with or without pre-treatment with sphingomyelinase, were incubated
and lysed with 50 µg/ml PLO, and the membranes were collected by centrifugation. The
membranes were washed three times with 5 mM HEPES buffer (pH 7.4) and mounted
onto carbon-coated grids (Formvar/copper, 200 mesh; Marivac Ltd., St.Laurent, QU)
followed by negative staining with sodium phosphotungstate (2% w/v, pH 7.4) for 5s.
Membranes were then examined in a LEO 912 AB Omega electron microscope operated
at 100 kV.
3.2.6 Protein Assay
Pyolysin concentrations were determined using Bradford assay or by the absorbance
at 280 nm and a calculated extinction coefficient of 68480 M−1.cm−1. The extinction
coefficient was calculated from the amino acid composition according to Pace et.al [118].
3.2.7 Spectrofluorimetry
Fluorescence measurements were taken using a PTI QuantaMaster spectrofluorimeter
(Photon Technologies Inc., London, Ontario, Canada). The excitation wavelengths were
289, 492 nm, and the emission wavelengths were 336, 520 nm for tryptophan and calcein,
respectively. The band pass was 2 nm for both emission and excitation.
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3.2.8 Binding of PLO to Liposomes
Multilamellar PC liposomes, with or without 50% by mole cholesterol, were prepared
as above, except that the membrane extrusion step was omitted. 100 µg/ml of solution-
derived oligomeric or of monomeric PLO were incubated with 500 µg/ml of these lipo-
somes. After 30 min incubation at 37◦C, the liposomes were sedimented by centrifu-
gation at 13,000 RPM in a table-top centrifuge for 15 mins, and the fraction of protein
remaining in the supernatant determined by protein assay.
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3.3 Results
3.3.1 Activity of PLO on Sphingomyelinase-Pretreated Erythrocytes
and Ceramide-Containing Liposomes
Compared to other CDC, the activity of pyolysin on sheep red blood cells is rather low;
in one of our initial experiments, we examined whether the susceptibility could be in-
creased by treatment of the cells with sphingomyelinase, which proved to be the case
(Fig 3.1). Figure 3.2 shows electron micrographs of red cell membranes with or without
sphingomyelinase pretreatment after exposure to the same amount PLO (80 µg/ml). The
difference in the number of pores on the membranes mirrors the difference in membrane
susceptibility.
Sphingomyelinase converts sphingomyelin to ceramide. The enhancement of mem-
brane susceptibility to pyolysin by ceramide was confirmed in a liposome model (Figure
3.3). Liposomes composed of 35% cholesterol and 20% ceramide by mole, with the bal-
ance being dimyristoyl-phosphatidylcholine (DMPC), leaked a fluorescent marker (cal-





















Figure 3.1: Hemolysis of human erythrocytes by PLO with and without pre-treatment
with sphingomyelinase (see meaterials and methods) . Red blood cells (0.5% by volume)
were exposed to various concentrations of PLO. Hemolysis was assayed by measuring
the OD540 of hemoglobin released into the supernatant.
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With Sphingomyelinase Without sphingomyelinase
Figure 3.2: Electron microscopy of pores formed by PLO on red blood cells with or with-
out pre-treatment with sphingomyelinase. Sheep red blood cell membranes, incubated























Figure 3.3: Calcein release assay for liposomes composed of 35% cholesterol and 35:20
cholesterol and ceramide by mole with PLO.
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3.3.2 PLO Permeabilizes Liposomes Containing Ceramide but no
Cholesterol
The observation that ceramide increases the susceptibility of liposome membranes also
containing cholesterol to PLO resembles previous findings with another CDC (strepto-
lysin O) and with Vibrio cholerae cytolysin, a structurally unrelated toxin that also re-
quires cholesterol for activity [184, 182]. In that study, the effect of ceramide was pro-
posed to be entirely indirect and to occur by enhancement of the interaction of the toxins
with cholesterol. Expecting a similar role of ceramide with pyolysin, we were surprised
to observe that liposomes containing 35% ceramide but no cholesterol were more suscep-
tible to PLO than those containing the same molar fraction of cholesterol but no ceramide
(Figure 3.4). Both liposome species were substantially less susceptible than those con-
taining the two lipids in combination, suggesting that a synergistic effect similar to the
previously reported one was operative, too.
3.3.3 The Effect of Ceramide and of Cholesterol Concentrations on
Membrane Susceptibility to PLO
The effectiveness of cholesterol in sensitizing lipid membranes to CDC is strongly de-
pendent on its concentration in the membrane [120, 119]; this was confirmed here with
pyolysin, which became far more active when the molar fraction of the sterol in liposome





















Figure 3.4: Calcein release assay for liposomes composed of 35% cholesterol and 35%
ceramide by mole with PLO.
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tration if ceramide showed only a minor enhancement on the susceptibility of liposomes
to PLO (Figure 3.5).
To test the possible effect of PLO on membranes containing lipids other than ce-
ramide, liposomes containing 50% dioleoylglycerol or phosphatidylethanolamine (which
are not closely related in structure to ceramide) or sphingomyelin were prepared and
tested by calcein release assay. None of these liposomes exhibited any calcein release
upon incubation with PLO; therefore, ceramide remains the only non-sterol lipid identi-
fied so far that does confer a low degree of susceptibility to PLO.
3.3.4 Oligomerization of PLO on Liposome Membranes
It has been reported that depleting cell membranes of cholesterol prevents permeabiliza-
tion by CDC at the stage of membrane insertion, while oligomerization remains possi-
ble, so that the toxin molecules accumulate as ‘pre-pore’ oligomers on the membrane
[49]. Since even at a ceramide fraction of 50% the susceptibility of liposome mem-
branes to PLO was relatively low, we asked whether the inefficiency of permeabilization
was caused at the stage of oligomerization or of membrane insertion. Oligomerization
of pore-forming toxins can be detected by proximity-based fluorescence assays such as
fluorescence quenching [69] or energy transfer (FRET) [69]). Figure 3.6 shows the flu-
orescence spectra of an equimolar mixture of fluorescein- and rhodamine-labeled PLO





















Figure 3.5: Calcein release assay for liposomes composed of 35% Ceramide and 50%





















Figure 3.6: Quenching of Rhodamine-labeled N90C PLO on liposomes of different com-
position.
FRET assay, it turned out to provide a rather more sensitive readout when assaying the
quenching of rhodamine fluorescence.
It is evident that the extent of fluorescence quenching is closely correlated with the
extent of membrane permeabilization. Quenching (indicative of oligomerization) is very
pronounced on the two most sensitive membranes studied, whereas it is minimal or ab-
sent with those membranes that have a low degree of susceptibility, including those con-
taining ceramide but no cholesterol. This suggests that the low degree of susceptibility
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to PLO conferred by ceramide is caused at or preceding the stage of oligomerization but
not only at membrane insertion. This suggestions led us to test the efficiency of binding
of PLO to ceramide containing liposome, the preliminary findings indicate low affinity
between PLO and ceramide containing liposomes. Further experiments are required to
test this process in more details.
3.3.5 The Role of Solution-Derived Oligomers in the Permeabiliza-
tion of Ceramide-Containing Liposomes
As shown in chapter 2, PLO was found to form solution-derived oligomers (SDO), which
are stable in solution; on erythrocyte membranes, they join into larger oligomers to form
pores and lyse the cells. The specific hemolytic activity of SDO is approximately four-
fold lower than that of monomers. Here, we tested the effect of SDOs and monomeric
PLO on liposomes with different lipid composition. Interestingly, we found that the
difference in activity is greater with liposomes containing cholesterol but no ceramide
(Figure 3.7).
In contrast, on liposomes containing ceramide but no cholesterol, the oligomer is


























Figure 3.7: Calcein release assay for liposomes composed of 50% Cholesterol by mole



















Figure 3.8: Calcein release assay for liposomes composed of 50% Ceramide by mole
with monomeric and oligomeric PLO.
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3.3.6 Binding of Solution-Derived Oligomers to Liposomes
Containing Cholesterol
The low activity of SDO on cholesterol-containing liposomes might conceivably be
caused at any stage of pore-formation, i.e.,during binding, oligomerization, or mem-
brane insertion. After incubation with multilamellar liposomes (which are convenient
for binding assays because they can easily be sedimented by centrifugation), 30% of
the monomeric PLO remained in the supernatant, indicating that 70% had bound to the
liposomes. In contrast, the absorbance of SDO remained virtually unchanged before and
after incubation with liposomes, indicating that the low activity of SDO towards chole-
sterol contains liposomes is due to low binding affinity.
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3.4 Discussion
Cholesterol-dependent cytolysins (CDC) are a group of bacterial toxins that have been
so called because of their apparently strict requirement for cholesterol in the target mem-
brane. We here provide evidence that, at least for one of these toxins, cholesterol is not
absolutely required. While it has been reported before that several structurally related
sterols can functionally replace cholesterol in model membranes [120], the current study
is the first one to show that membranes entirely devoid of any sterol can be susceptible,
too.
The lack of PLO activity towards liposomes containing dioleoylglycerol, phosphati-
dylethanolamine or sphingomyelin, indicates that ceramide is, to some degree, specifi-
cally required for this interaction. This supports the notion that the effect of ceramide
reported here is truly distinct from that described in a previous study [182], in which
the activity of streptolysin O and Vibrio cholerae cytolysin on membranes containing
cholesterol was synergistically enhanced by ceramide but also by dioleoylglycerol or
phosphatidylethanolamine. In that previous study, the synergistic effect of ceramide and
several other lipids was proposed to be due to their cone shape and to be mediated by an
increase in the chemical potential of cholesterol. According to this interpretation, syn-
ergism of ceramide and cholesterol should affect any protein that depends on membrane
cholesterol; it should therefore be and was indeed here observed with pyolysin as well.
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It was pointed out above (page 21) that some argument exists about the stage of
pore-formation that involves cholesterol; while several studies support the notion that it
is involved in membrane binding of the toxin, it has also been proposed that its main
contribution consist in facilitating the insertion of the already assembled pre-pore [49].
The observations of the current study provides additional insight into the interaction of
CDCs with lipid membranes and the role of cholesterol.
The first observation is that the activity of pyolysin on ceramide-containing mem-
branes is much lower than that observed with cholesterol-containing membranes. This
low activity might conceivably be caused at any of the three major stages of pore-
formation, i.e.,membrane binding, oligomerization, or membrane insertion. Oligomer-
ization was barely detectable in the fluorescence quenching assay. Preliminary experi-
ments with multilamellar liposomes indicate that, at least with monomeric PLO, binding
is inefficient, too, supporting the traditional notion that cholesterol is involved in bind-
ing. It still remains to be determined how effectively the minor fraction of PLO that
does remain bound proceeds with oligomerization and membrane insertion. In addition,
the binding affinity of solution-derived oligomers (SDO), which had a slightly higher
specific membrane-permeabilizing activity, must be determined as well.
A role of cholesterol in toxin binding is also consistent with the observation that SDO
bind much less efficiently than the monomeric toxin to liposomes containing cholesterol
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but no ceramide. If binding and even formation of the oligomeric pre-pore could pro-
ceed in the absence of the sterol, it would be difficult to understand why pre-formed
oligomers (SDO) should not bind equally well as the monomers. Even assuming that
cholesterol does have a role in binding, the current observation remains intriguing: Pre-
oligomerization might be expected to aggregate multiple sterol binding sites and there-
fore increase rather than decrease binding affinity. Therefore, the lowered affinity of
SDO for cholesterol-containing membranes suggests that the binding site for the sterol
that is available in the monomer may be hidden in the SDO. To the extent that the SDO
structurally resembles the oligomeric pre-pore that forms on membranes, the low affinity
of the SDO suggests that the pre-pore may no longer interact with the sterol. How-
ever, this would contradict the previous assertion of an involvement of cholesterol in the
membrane insertion of the pre-pore [49]; therefore, this question needs to be investigated
further.
Keeping in mind that SDO are still hemolytically active (see 57), the fact that they
almost fail to bind to cholesterol-containing liposomes would suggest a possible role
of membrane components other than cholesterol in the binding of PLO to erythrocyte
membranes. The previous reports on the binding of intermedilysin [50] and of other
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4.1 Introduction
CAMP factor is a 26 kDa extracellular cytolysin secreted by Streptococcus agalactiae. In
addition to this cytolytic activity, CAMP factor was reported to bind to immunoglobulins
G and M in a manner similar to protein A of Staphylococcus aureus, and it was therefore
given the alternative name ‘protein B’ [77]. Somewhat unfortunately, that same name
(Protein B) has also been applied to another protein produced by Group B streptococci,
which has a molecular weight of 130 kDa and binds to IgA [29, 40, 57]. The interaction
between CAMP factor and immunoglobulins reportedly inhibits the co-hemolytic activ-
ity of CAMP factor [77]. CAMP factor does not share significant homology with protein
A, protein G, or any other known antibody-binding protein.
Binding of protein A to the Fc domains of immunoglobulins inhibits the hemolysis
mediated by complement [146], suggesting that the finding that the binding sites for
protein A and the complement component C1q overlap [81]. In the present study, we
intended to examine the possibility of a similar effect with CAMP factor in order to
gain insight into the relationship of the binding sites for C1q and CAMP factor. No
inhibition of complement-mediated hemolysis was observed. We therefore re-examined
the binding of CAMP factor to IgG in more detail. The results indicate that CAMP factor
is not endowed with non-immune binding to IgG.
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4.2 Materials and Methods
4.2.1 Expression and Purification of Wild Type and Recombinant
CAMP Factor
Wild type CAMP factor was purified from a clinical strain of S. agalactiae (obtained
from the Grand River Hospital, Kitchener, ON, Canada). A liquid culture (500 ml Todd-
Hewitt broth with 2 % glucose) was grown at 37◦C and adjusted to pH 6.2 every 15
minutes using a sterile-filtered equimolar solution of glucose and sodium bicarbonate.
When the culture had reached the stationary phase, the cells were centrifuged at 15,000
g for 15 minutes and the supernatant precipitated using ammonium sulphate (65 % sat-
uration). After centrifugation at 53,000 g for 15 minutes, the pellet was resuspended
in 5 mL PBS (16 mM K2HPO4, 150 mM NaCl, pH. 7.5). The sample was applied to
a chromatography column packed with ceramic fluoroapatite (BioRad) and equilibrated
with 10 mM potassium phosphate buffer (pH 7.2). The column was eluted using a linear
gradient of potassium phosphate buffer (10-400 mM, pH 7.2). The recombinant wild
type CAMP factor and the single cysteine mutant F109C were prepared as described by
Lang and Palmer [82].
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4.2.2 Fluorescein Labeling of Mutant Recombinant CAMP Factor
The CAMP factor mutant F109C was transferred into 50 mm Tris, 150 mm NaCl, 1 mm
EDTA, pH 7.5 by gel filtration on a PD10 column (Pharmacia). A 5-fold molar excess of
fluorescein maleimide (Molecular Probes) was then added and the mixture was incubated
at room temperature for 30 minutes. Unreacted fluorescein maleimide was removed by
another round of gel filtration.
4.2.3 Hemolysis Assay of Inhibition of Complement Activation
400 µl of 10 % sheep red blood cells were washed four times with Hepes-buffered saline
(HBS; 25 mM Hepes, 150 mM NaCl, 2.5 mM MgCl2, 0.75 mM CaCl2, pH. 7.2) and
suspended to a final erythrocyte concentration of 4 % in HBS. 200 µl of cell suspension
was added to 200 µl of ‘hemolysin’ (rabbit anti-sheep) antibodies (Cedarlane, Hornaby,
ON) and incubated for 30 minutes at room temperature. The cells were pelleted by
centrifugation at 2500 g for 4 minutes and washed for 4 times with HBS by resuspension
and centrifugation. After resuspending in 200 µl of HBS, 50 µl were transferred to a
series of microcenrifuge tubes either containing 50 µl of HBS, wild type CAMP factor,
recombinant CAMP factor, or protein A (final protein concentration 50 g/mL each). The
tubes were incubated for 30 minutes at room temperature. Each tube was supplemented
with 200 µl of diluted rabbit serum and incubated for 1 hour at 37◦C. After spinning
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down membranes and unlysed cells at 2500 x g for 4 minutes, hemolysis was measured
by the absorbance of the released hemoglobin (A445).
4.2.4 Co-hemolytic Activity Assay
Sheep red blood cells (Cedarlane, Hornby, Ontario, Canada) were washed five times
in hemolysis buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) by centrifugation. The
erythrocytes were then resuspended in hemolysis buffer to 0.5 % (v/v). The cells were
incubated at room temperature for 5 min in the presence of 10 mM MgCl2 and with 50
milliunits/ml of sphingomyelinase from S. aureus (EC 3.1.4.12, Sigma). 180 µl of cell
suspension were added to the wells of a microplate containing serial dilutions of CAMP
factor in 20 µl of the former buffer and incubated for 30 minutes at 37◦C. After spinning
down membranes and unlysed cells at 2500 g for 4 minutes, hemolysis was measured by
the absorbance of the released hemoglobin (A445). Control samples incubated without
CAMP factor remained stable during the assay period.
4.2.5 Size Exclusion Chromatography
Size exclusion chromatography was performed using a Superdex 200 column (Amer-
sham) equilibrated with PBS. The flow rate was maintained at 0.3 mLmin-1 with an
KTApurifier chromatography system (Amersham Biosciences, Baie d’Urfe, QC, Canada).
The elution profile was monitored by online measurement of the A280 (for unlabeled pro-
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teins) or A492 (for fluorescein-labeled CAMP factor). The eluate was collected in frac-
tions of 0.3 ml, which were either examined by fluorimetry (see below) or precipitated
with trichloroacetic acid (5 % final concentration) for analysis by SDS-PAGE.
4.2.6 Electrophoresis
SDS-PAGE was performed according to Laemmli [80], using polyacrylamide concentra-
tions of 4% in the stacking gels and of 12% in the resolving gels. Gels were stained with
Coomassie blue.
4.2.7 Spectrofluorimetry
Fluorescence measurements were taken using a PTI QuantaMaster spectrofluorimeter.
The excitation wavelengths were 492 and 289 nm, and the emission wavelengths were
520 and 336 nm for fluorescein and tryptophan, respectively. The band pass was 2 nm
for both emission and excitation.
4.2.8 Protein Assay




Positive ion electrospray mass spectrometry was performed on a Micromass Q-Tof Ul-
tima GLOBAL mass spectrometer. The proteins were transferred to 20 mM ammonium
acetate (pH 7.0) buffer using PD-10 columns, lyophilized overnight and dissolved to ap-
proximately 10 M in 1:1 acetonitrile/water solution containing 0.2 % formic acid. The
samples were infused at 0.8 l/min. Raw data (m/z) were processed using MaxEnt1 soft-
ware to yield spectra on a true molecular mass scale.
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4.3 Results
Initial experiments were performed with recombinant CAMP factor expressed in E. coli.
To rule out the possibility that the observed lack of binding to IgG is due to the slight
changes of the primary structure that result from the recombinant expression system [82],
wild type CAMP factor purified from S. agalactiae was included in the experiments
as well. The wild type CAMP factor purified from S. agalactiae showed the expected
molar mass of 23856 Da (Figure 4.1). Its co-hemolytic activity was similar to that of
recombinant CAMP factor (Figure 4.2).
4.3.1 CAMP Factor Does Not Inhibit Antibody/Complement-Mediated
Hemolysis
At the outset of this study, we intended to characterize the effect of the purported bind-
ing of CAMP factor to Fc domains of IgG on the latter’s ability to inhibit hemolysis
mediated by complement. We used the hemolysis assay that underlies the complement
fixation test. In this assay, sheep red blood cells are coated with rabbit anti-sheep (‘hemo-
lysin’) antibodies, which will activate complement and cause it to lyse the cells. Figure
4.3 shows that, as has been described previously [146], protein A indeed strongly in-
hibits complement-mediated hemolysis, indicating that its binding to the Fc domains of
the hemolysin antibodies prevents these from activating serum complement. In contrast,
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Figure 4.1: Mass spectrometry of wild type CAMP factor purified from S. agalactiae.
The peak at 23,856 Da corresponds to wild type CAMP factor; the secondary peak at




























Figure 4.2: Co-hemolytic activity of wild type and recombinant CAMP factor.
Sphingomyelinase-treated erythrocytes were incubated for 30 min with the amounts of
wild type and recombinant CAMP factor indicated. The samples were centrifuged and
the extent of hemolysis determined from the absorbance (A445) of hemoglobin released
into the supernatant.
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bition. Figure 4.3 also shows that CAMP factor alone did not cause hemolysis, as the
cells were not sensitized with sphingomyelinase; therefore, the lysis observed with the
samples containing both complement and CAMP factor was indeed due to complement
activation.
4.3.2 Immunoglobulin G Does Not Inhibit the Co-Hemolytic Activ-
ity of CAMP Factor
It has been reported that the non-immune binding to IgG inhibits the co-hemolytic activ-
ity of CAMP factor [77]. In this study, we tried to reproduce this inhibitory effect, using
various molar ratios of IgG to CAMP factor. However, as shown in Figure 4.4, neither
wild type nor recombinant CAMP factors were inhibited to any extent even with IgG
present in large molar excess.
4.3.3 CAMP Factor Does Not Bind Human Immunoglobulin G
The previous observations led us to re-examine the binding of CAMP factor to IgG. We
chose to employ the same assay that was used in the preceding study, i.e.,co-incubation of
IgG with CAMP factor, followed by analysis of the sample by size exclusion chromatog-
raphy. First, fluorescein maleimide-labeled recombinant CAMP factor was incubated
with a twofold molar excess of human IgG for 30 minutes at 37◦C before application to
































Figure 4.3: Hemolysis assay for inhibition of complement activation. Sheep erythro-
cytes were sensitized with rabbit anti-sheep IgG. They were then treated with protein A,
recombinant (rec) or wild type (wt) CAMP factor as indicated before incubation with a
source of complement (rabbit serum). Hemoglobin release from lysed cells was mea-
sured by the absorbance at 445 nm. Control samples with recombinant or wild type
CAMP factor show that these alone do not cause hemolysis under the given conditions.
complement-mediated hemolysis, indicating that its binding to the Fc domains of the
hemolysin antibodies prevents these from activating serum complement. In contrast,
neither recombinant nor wild type CAMP factor show any degree of complement inhibi-
tion.
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Since IgG was used in excess and contains multiple tryptophan residues, whereas only
one tryptophan residue occurs in CAMP factor, tryptophan fluorescence essentially coin-
cides with the distribution of IgG; fluorescein is associated only with CAMP factor. The
two proteins are clearly separated, with IgG being eluted at 12.7 ml and CAMP factor
the 15.8 ml (Figure 4.5A), indicating a lack of binding between CAMP factor and the
IgG.
To exclude any possibility that the recombinant expression or covalent labeling of
CAMP factor had interfered with the binding of CAMP factor to IgG, the size exclusion
chromatography was repeated using unlabeled wild type CAMP factor. In this experi-
ment, the collected fractions were precipitated with TCA and subjected to SDS PAGE
(Figure 4.5B). Again, no CAMP factor was found in the fractions containing IgG, thus






























































Figure 4.4: Co-hemolytic activities of wild type and recombinant CAMP factor in the
presence of human IgG. Sheep red blood cells were pretreated with 25 mU/ml sphin-
gomyelinase at room temperature for 30 minutes. They were then added to mixtures of
IgG with wild type (A) and recombinant (B) CAMP factor (molar ratios as indicated).
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Figure 4.5: A. Analysis of CAMP factor binding to IgG by size exclusion chromatog-
raphy. A: Tryptophan and fluorescein fluorescence profiles of a mixture of fluorescein-
labeled recombinant CAMP factor with unlabeled IgG. Due to the use of IgG in 5 fold
molar excess and the low abundance of tryptophan in CAMP factor, the tryptophan fluo-
rescence trace mostly reflects the distribution of IgG. B. SDS-PAGE of fractions obtained
from a mixture of wild type CAMP factor with a twofold molar excess of IgG. m, molec-
ular weight marker. M, High molecular weight marker, lanes 1-7 represent the fractions
collected between volume 11.3 and 14.9 ml, whereas lanes 11-15 represent the fractions
collected between volume 15.4 and 16.6 ml. Lanes 9 and 17 are CAMP factor, lane 8
and 16 is human IgG.
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4.4 Discussion
The results of the present study all support the conclusion that CAMP factor does not
bind to immunoglobulin IgG. These results do not match with the reported findings re-
garding the binding of CAMP factor to the Fc fragment of immunoglobulin [77]. Indirect
support for our conclusion comes from another previous study, which examined the re-
action of CAMP factor with sera from adults and newborns infected with S. agalactiae
as well as healthy control persons [43]. While sera of infected newborns and adults did
react with CAMP factor, only 2 out of 11 sera from healthy teenagers gave a positive
reaction, indicating that CAMP factor only reacts with specific antibodies, i.e.,via the
Fab domain. If CAMP factor could indeed bind to the Fc domain, a (false) positive
reaction binding should have been observed with all serum samples, regardless of the
patients’ previous exposure and acquisition of immunity to S. agalactiae. In all of the
previous experiments that indicated binding of CAMP factor to Fc fragments of IgG and
IgM [77], the immunoglobulins were used in 25-fold or higher molar excess over CAMP
factor. CAMP factor is a small molecule (25 kDa), and the number of its binding sites
for antibody molecules should be limited. The need for far higher than stoichiometric
amounts of antibody might suggest a very low affinity of binding; however, as we were
unable to reproduce the reported inhibitory effect of IgG on CAMP factor activity even
at the same very high ratios, this explanation does not fit our results. Alternatively, the
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previously reported effects may have been due to some contaminating protein in the an-
tibody preparation. We conclude that CAMP factor does not bind to human IgG and,
most likely, other immunoglobulins; its well-characterized co-hemolytic effect remains
the only known activity of this protein. The name protein B in substitution for CAMP
factor is therefore not appropriate.
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Chapter 5
Summary and Future Considerations
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The studies on pyolysin presented in this thesis have shown:
1. PLO forms small oligomers in solution. This observation agrees with previous
reports on the formation of solution-derived oligomers by other CDCs [51].
2. The conformation of PLO within solution-derived oligomers (SDO) resembles the
monomer or pre-pore and distinctively deviates from the inserted pore.
3. SDO will not dissociate on erythrocyte membranes but will coalesce into larger
oligomers that then insert and form pores.
4. Pores derived from SDO tend to be arc-shaped and show reduced functional diam-
eters, corroborating the notion [121] that arcs are indeed functional pores.
5. SDO have reduced activity on PC/cholesterol liposomes, which is due to reduced
binding; this suggests that the cholesterol binding site is masked in the SDO, and
that the oligomer at some point of its formation or maturation ceases to interact
with cholesterol. It is still possible that cholesterol may become involved with the
oligomer again at the final stage of membrane insertion.
Future experiments should elucidate the interaction of PLO with ceramide and with
natural cell membranes:
1. In this study, N-Lauroyl-D-erythro-sphingosine (C-12 Ceramide) was the only ce-
ramide tested. To determine the structural features of the ceramide molecule re-
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sponsible for this sensitizing action, it would be worthwhile to compare the effects
of other ceramides with different carbon chain lengths, as well as other ceramide
derivatives (for example, using ceramides in which the C4-C5 double bond is re-
placed by a triple bond, a cyclopropyl group, or a benzene ring [182]).
2. Although the fact that SDO are more active than monomeric PLO suggests that
oligomerization is required for permeabilization of ceramide-containing membranes,
it has not been directly demonstrated that oligomerization does indeed occur on
such membranes. This should be addressed with more sensitive assays of oligomer-
ization, possibly involving separation of oligomers from monomers by size.
3. From the fairly high concentrations of pyolysin required to permeabilize mem-
branes containing ceramide but not cholesterol, we can conclude that the specific
activity of toxin on such membranes is low. While prelimary results suggest that
this is due to low binding affinity, it would be valuable to use more sensitive and
quantitative assays to measure binding affinity (this may include fluorescence tech-
niques as well as surface plasmon resonance).
4. Our findings that SDO does not bind to cholesterol liposomes, while it is hemolyt-
ically active, would suggest a possible role of membrane receptors on red blood
cells. It would be worthwhile investigating this possibility.
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Streptococcal CAMP factor was previously reported to bind to the Fc fragment of
IgG and therefore was called Protein B [77]. We have shown here that such binding does
not occur. Likewise, we were unable to reproduce the reported inhibitory effect of IgG
on the co-hemolytic activity of CAMP factor.
The negative findings of our study do not encourage any further research on the inter-
action of CAMP factor with immunoglobulins. Future studies should focus on more fully
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